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ABSTRACT OF THE DISSERTATION 
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by 
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Miami, Florida 
Professor David A. Becker, Major Professor 
 Steroids are one of the essential classes of bioactive compounds and are involved 
in many biological functions which include their role as signaling compounds, the 
alteration of membrane fluidity and the regulation of a variety of metabolic processes. In 
order to identify novel compounds with beneficial pharmacological action, the synthesis of 
modified steroids is gaining much attention in recent years. Among those analogs, 
azasteroids are one of the most important classes which display a variety of biological 
activities, often free from undesirable side effects. The challenges in the synthesis of 
steroids, particularly azasteroids, and the potential of azasteroids as novel drugs has 
prompted numerous investigations in this field. The synthetic methods leading to steroidal 
derivatives (azasteroids) with one or more nitrogen atoms are very limited. Generally, 
oxidative cleavage of the steroidal rings is needed to introduce nitrogen atom(s) in order to 
synthesize azasteroids.  
 In the first part of this dissertation, explorations into the synthetic methods needed 
for making a new steroidal A-ring or seco A-ring on a tricyclic benz[e]indenedione (a dimer 
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compound obtained in connection with continued work on the study of anhydrobases of 
the isoxazole series) were pursued. In this process, a series of three tricyclic hydrazone 
compounds have been designed and synthesized to mimic the tetracyclic rigid core 
structure of azasteroids. We are eager to ascertain if these compounds possesses any 
interesting biological properties. 
 In continued research on the synthesis of azulenyl and pseudoazulenyl nitrones, (to 
target ROS generation at the site of mitochondria), the second part of this research was 
aimed at the synthesis of cationic pseudoazulenyl nitrones with mitochondriotropic 
properties. Several pseudoazulenyl nitrone derivatives were synthesized using the natural 
compound valtrate, obtained from the roots of Centranthus ruber. Unfortunately, the 
attempts made to convert these compounds into the corresponding cationic pseudoazulenyl 
nitrones failed. However, an interesting pseudoazulenyl dinitrone molecule bearing an 
imidazole group was prepared. Also, a pseudoazulenyl mono nitrone compound with an 
electron donating group was synthesized by leaving a highly reactive aldehyde 
functionality intact for further use in synthetic study.  
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AZASTEROIDS 
CHAPTER 1: INTRODUCTION 
Azasteroids are steroid mimics, a class of natural or synthetic compounds, 
containing nitrogen in a cyclopentenophenanthrene steroidal nucleus. The replacement of 
one or more carbon atoms of a steroidal molecule with a heteroatom affects chemical 
properties and can produce useful alterations in its biological activities.1 Heterosteroids and 
specifically azasteroids, have received much attention among structurally modified natural 
steroids because of their wide variety of biological activities, often free from undesirable 
or harmful side effects.1-3 One could divide azasteroids into two categories, nuclear and 
exonuclear, determined by the position of heteroatoms. The compounds in which 
replacement of carbon atom in the steroidal skeleton at positons 1-17 are nuclear, whereas 
in the side chain or in extra rings are exonuclear. Nuclear azasteroids are further classified 
by the position (1-17) of heteroatom or by the ring (A-D) of the steroidal skeleton. For 
example, Finasteride and Dutasteride (Avodart) are synthetic, A-ring 4- azasteroids used 
as 5α-reductase inhibitors. The series of A25822 (A, B, D, L, M, N), natural, homo-D-ring 
15-azasteroids was isolated from the mold Geotriclzum flavor-brunneum in 1975.4 
 
Figure 1. Examples of biologically active azasteroids. 
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1.1 Biological importance  
Steroids are one of the most important classes of molecules and perform a number 
of fundamental biological functions. These natural and synthetic drugs get great attention 
in research because of such interesting biological properties3 and many have an ability to 
cross cell membranes readily.3, 5 In order to find new steroidal molecules with desirable 
biological effects, natural steroids are often modified at several positions, especially in the 
cyclopentenophenanthrene ring system with heteroatoms or rings.6 Replacement of one or 
more atoms in steroids with heteroatoms (nitrogen) generates new molecules called 
azasteroids with such diverse biological properties as cytotoxicity, anti-atherogenicity, 
anti-carcinogenicity, antifungal, antilipemic, local anaesthetic, neuromuscular blocking 
activity, inhibition of steroidal reductases, and more.7-12  Certain azasteroidal pills are well 
known contraceptive drugs, because of their binding with steroid receptors, thereby 
blocking the binding of the actual steroids.13-14 Enzymes that normally transform steroids 
may bind with substrates and form undesirable steroids. Certain azasteroids have an ability 
to block the biosynthesis of physiologically undesirable steroids. 
Finasteride is a synthetic azasteroid derived from progesterone. It is a specific 
inhibitor of steroid 5α-reductase type-II, an intracellular enzyme that converts the androgen 
testosterone into 5α-dihydrotestosterone (DHT).15 The DHT is responsible for the 
development and enlargement of the prostate gland called Benign Prostatic Hyperplasia 
(BPH). Dutasteride (Avodart) is also a synthetic drug used to treat hair loss and prostate 
enlargement in men. Avodart is considered to be a dual 5α-reductase inhibitor because it 
suppresses both isomers of the enzyme (type-I and type-II).16-17 The activity of inhibition 
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of the generation of DHT is called antiandrogenic activity. Another azasteroid, RU-5135, 
contains nitrogen in the steroid D ring and it acts as a GABA receptor antagonist.18 
1.1.1 Benign prostatic hyperplasia (BPH) and 5α-reductase inhibitors 
Benign prostatic hyperplasia known as BPH is a condition of prostate gland 
enlargement and which is not malignant prostate cancer.  The unwanted enlargement of the 
prostate gland may start during its second phase of natural   growth in almost all men at the 
age of 25 and continues rest of the life. After several years of enlargement, the gland presses 
against the urethra, makes the urethra bladder walls weaker and unable to empty 
completely by leaving some urine unextruded. Ultimately this leads to many other BPH 
related problems such as urinary related infections (Lower Urinary Tract Symptoms, 
LUTS), kidney damage, kidney stones, bladder damage and more.17  
Generation of androgens at normal levels plays an important role in the necessary 
growth and development of the prostate gland. In other cases, abnormal androgen levels 
may lead to prostate cancer, BPH, acne and other diseases.17 Dihydrotestosterone (DHT) 
is one type of androgen sex steroid, generated from testosterone in the presence of 5α-
reductase enzyme and NADPH. Dihydrotestosterone is involved in the growth of the 
prostate gland which is necessary for the development of male secondary sex 
characteristics. Accumulation of DHT can lead to BPH in older men as they continue to 
produce it even at the age of 70. Scientists found that there is no BPH in men who are 
unable to produce DHT.15-17  
The enzyme, 5α-reductase, is responsible for the conversion of testosterone to 5α-
dihydrotestosterone. The physical appearance of genetic males with deficiency in 5α-
reductase is feminine. After a certain age in normal males, 5α-reductase creates urinary 
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problems by continuous production of DHT, which is responsible for prostate development 
as well as the pathogenesis of BPH and male-pattern baldness. There are three types of 5α-
reductase enzymes and type-2 is the one that is mainly responsible for the generation of 
DHT.16  
 
Figure 2. Conversion of testosterone to DHT. 
The inhibitors of the 5α-reductase, especially the steroidal type, quench the 
generation of DHT by blocking the enzyme 5α-reductase and it leads to a reduction in the 
size of the prostate gland.17 The activity of 5α-reductase inhibitors engender the increased 
levels of testosterone and decreased levels of DHT. By inhibiting DHT, 5α-reductase 
inhibitors reduce the effects of androgens such as DHT on the prostate. These inhibitors 
are used to treat BPH, prostate cancer, and baldness. Much research focused on these 5α-
reductase inhibitors for the identification of a potential drug to treat androgen related 
complications. In this process of identification of potential drug, several diverse 
compounds were synthesized but the azasteroids drew more attention than steroidal/non-
steroidal compounds because of their relatively facile and attractive biological properties.  
Two drugs currently available in this steroidal class are Finasteride and Dutasteride. 
These two medications differ because of their levels of inhibition of the conversion from 
testosterone to dihydrotestosterone.16 Dutasteride has a greater ability in suppression of 
 5 
 
DHT than Finasteride by inhibiting both type-1 and type-2 5α-reductases while Finasteride 
inhibits type-2 alone. Also Dutasteride is superior to Finasteride in estimated half-life with 
approximately five weeks as that of the latter is only five to eight hours.17  
Finasteride is used to treat men with BPH, alone or in combination with other 
medicines such as alpha-blockers. Finasteride is also used to treat male pattern hair loss, 
the gradual thinning of men’s hair which leads to the balding on the top of the scalp. 
Finasteride will increase the growth of scalp hair but not the body hair by blocking only 
the production of a male hormone in the scalp that stops hair growth. The effect of 
Finasteride will stay as long as the medicine is taken. When it is stopped, the prostate begins 
to grow and hair loss increases. 
1.1.2 Azasteroids as Selective androgen receptor modulators (SARMs)  
Selective androgen receptor modulators (non-steroidal) are a novel class of 
therapeutic compounds having properties similar to anabolic-androgenic steroids (AAS) 
but more selective in their action.19 Such selectivity includes androgen receptor specificity, 
tissue selectivity, fewer steroid-related side effects and, most importantly, an ability to 
differentiate between anabolic and androgenic activities.20 These exceptional properties 
make SARMs unique in the treatment of androgen related complications although they do 
have the potential for misusage as performance enhancement drugs in sports because of 
their anabolic properties and an ability to stimulate androgen receptors.21 
In the process of finding new SARMs, several azasteroidal androgen receptor 
agonists were designed and synthesized from DHT.22-24 These new azasteroidal selective 
androgen receptor modulators 1-3 showed potent hAR binding, low virilizing potential and 
a favorable pharmacokinetic profile in dogs.22 Several other patented compounds were also 
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reported by virtue of their clinical properties that were useful for the enhancement of 
weakened muscle tone and amelioration of complications generated by androgen 
deficiency such as osteoporosis, atherosclerosis, obesity, BPH, prostate cancer, etc.23-24  
  
Figure 3. Selective androgen receptor modulators (SARMs) of azasteroids. 
1.1.3 Neuromuscular Blockers  
Neuromuscular blockers are used clinically as an adjunct to anesthesia to provide 
muscle relaxation during surgery. Before introduction of neuromuscular blockers, 
anesthesia was used to maintain muscle relaxation bearing the risk of respiratory or cardiac 
depression. During surgical operations, it is necessary to control spontaneous movement 
of muscles. Compounds with quaternary ammonium groups (usually two) in their structure 
are common muscle relaxant drugs. These relaxant drugs mimic the action of acetylcholine 
and prevent the transmission of signaling muscle neurons by blocking the nicotinic 
acetylcholine (ACh) receptors.25 
A revolution took place in the field of anesthesia after isolation of d-tubocurarine, 
a mono quaternary alkaloid extracted from a native plant of Central and South America, 
Chondodendron tomentosum, in 1942. The compound d-tubocurarine is historically known 
as an arrow poison and it has paralyzing activity. Neuromuscular blockers are classified 
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into two categories: Depolarizing and Non-depolarizing, defined by their mechanism of 
action.25-28  
Depolarizing neuromuscular blockers: This type of neuromuscular blockers 
blockade of ACh receptors create by occupying and activating the nicotinic receptors for a 
prolonged period of time. The structures of the depolarizing neuromuscular blockers 
resemble that of Ach. Succinylcholine (SCh) is the only drug available in this class of 
neuromuscular blockers. Succinylcholine has two acetylcholine molecules connected at 
their acetyl groups. Succinylcholine is also called Suxamethonium chloride and it is used 
in emergency medicine to cause quick and short term muscle relaxation. It has a rapid onset 
of action about 30 seconds with a duration of action of about five to eight minutes.25-28  
 
Figure 4. Structures of acetylcholine and Succinylcholine. 
Succinylcholine mimics the action of acetylcholine by binding to acetylcholine receptors 
in the neuromuscular junction.25 These receptors open their channel allowing sodium ions 
to flow into the muscle cells and potassium ions to rush out. The ion flow causes 
depolarization in muscle cells and it leads to the initial muscle contraction called 
fasciculation, and subsequently, to paralysis. Succinylcholine has a prolonged 
depolarization effect under the influence of acetylcholinesterase inhibitors. Because of this 
prolonged endplate depolarization, normal neuron transmission to muscle cannot produce 
muscle contraction. Succinylcholine can cause many side effects, such as hyperthermia and 
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hyperkalemia. The latter one occurs as a result of increased potassium levels in serum 
which leads to nerve damage and then subsequently to cardiac arrest.  
 
Figure 5. Non-depolarizing neuromuscular blocking agent, Tubocurarine. 
Non-depolarizing neuromuscular blockers: These neuromuscular blockers bind 
to the same nicotinic ACh receptor, but do not open up the sodium channel, and thus, do 
not polarize the motor endplate.25 These non-depolarizing agents simply antagonize the 
actions of ACh at nicotinic acetylcholine receptors by blocking them, so there is no muscle 
contraction and depolarization because ACh cannot transmit the nerve impulses. The 
blockage can be reversed by increasing the concentration of ACh. The structures of these 
blockers are bulky and rigid, and most of them have quaternary ammonium moieties. The 
drugs of this category of agents is further divided into two groups, aminosteroids and 
benzylisoquinolinium derivatives. Tubocurarine is a natural benzylisoquinolinium 
compound and was the first neuromuscular blocking agent isolated from plants by South 
Americans, who used it to paralyze their prey. Later on, several related synthetic agents 
were developed.25-33  
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1.1.4 Aminosteroid or Azasteroid neuromuscular blockers  
Neuromuscular blockers are further divided by their structure; steroidal 
(azasteroidal) or non-steroidal. Aminosteroids are non-depolarizing agents and constitute 
most of the neuromuscular blockers.25 These agents have a common steroidal rigid 
structure with two quaternary ammonium moieties.29 Aminosteroids block neuromuscular 
activity either by binding Ach receptors or by blocking ionotropic activity of Ach. A range 
of aminosteroids, with positive neuromuscular blocking activity, have been synthesized 
with a varying degree of flexibility in their steroidal structures. Some of them have been 
used as successful drugs and commercialized as curariforms, such as Pancuronium, 
Pipecuronium, Rocuronium and Vecuronium.30-33  
 
Figure 6. Azasteroidal neuromuscular blockers. 
Pancuronium or Pancuronium bromide is a non-depolarizing neuromuscular 
blocking agent that acts by blocking cholinergic receptors at the motor end-plate. It is more 
potent and possesses a longer duration of neuromuscular blockage than Tubocurarine. 
Rapacuronium and Rocuronium are analogues of Pancuronium. Other neuromuscular 
blocking agents such as Vecuronium, Atracurium and Pipecuronium have a similar clinical 
activity as that of Pancuronium. Animal experiments exploring the activity of 
Pipecuronium have shown that the activity of Pipecuronium is four times that of 
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Pancuronium and the duration of action is twice that of Pancuronium. Several other 
azasteroid neuromuscular blockers with promising clinical activities have been 
discovered.29 
1.1.5 Neurosteroids  
In the mammalian brain, gamma-Aminobutyric acid (GABA) and glutamate (Glu) 
are the most abundant inhibitory and excitatory neurotransmitters.34 Over half of all the 
brain’s neurotransmitters are glutamergic, and 30-40 % are GABAergic.34-36 Glutamate is 
actually a metabolic precursor of GABA, and the conversion from glutamate to GABA is 
controlled by an enzyme called glutamic acid decarboxylase (GAD). The fundamental 
function of GAD is that of keeping GABA and Glu properly balanced in order to maintain 
regular functioning of the CNS. Brain disorders such as anxiety, depression and 
schizophrenia are the result of an imbalance between excitation and inhibition activities.37 
Gamma-Aminobutyric acid plays a crucial role in neurons. Changes in GABA metabolism 
such as a decrease in GABA or GABAergic neurons leads to the generation of most of the 
brain’s neuron related disorders.38  
 Several synthetic and natural medications are available for the treatment of GABA-
Glu balance disorders and they are categorized based on their action on GABA-Glu 
receptors. Most importantly, GABA (A&B) receptor agonists are the major class of 
therapeutic compounds (which includes PAMs-positive allosteric modulators- such as 
alcohols, barbiturates and benzodiazepines) which indirectly influence or enhance the 
activity of GABA receptors. The GABA receptor antagonist, and N-methyl-D-aspartic acid 
(NMDA) receptor (a glutamate receptor) antagonists are some of the other classes of 
medications.35-40  
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Figure 7. Structure of GABA and Glutamate. 
 Neurosteroids are the natural/synthetic steroids that modulate GABA and 
glutamatergic neural communications. These have received wide attention recently as they 
are produced endogenously in the brain and affect the activity of GABA-Glu receptors.40 
Synthetic analogues of these endogenous steroids are also useful as anticonvulsants, 
neuroprotectants and as anesthetics.39 Althesin, alphaxalone (one of the constituent of 
althesis) and endogenously produced anesthetics such as allopregnanolone and 
pregnanolone are shown to be GABAergic neurotransmitters. Some endogenous steroidal 
precursors, pregnenolone sulfate (PREGS) and dehydroepiandrosterone sulfate (DHEAS), 
were shown to suppress neural activity by diminishing GABAergic neurotransmission.40 
The PREGS also showed enhancement of NMDA receptor function. It has been clear that 
neurosteroids show activity at both types of receptors, but GABAergic agonists and 
blockers of NMDA receptor neurotransmissions are associated with anticonvulsant, 
neuroprotectant and anesthetic properties.40 
 
Figure 8. GABA and glutamatergic neurotransmitters/ neurosteroids. 
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 Benz[e]indenes, tricyclic non-steroidal compounds having a structural framework 
similar to steroids such as pregnanolone and allopregnanolone, showed enhanced 
GABAergic transmissions by mimicking the structural properties of steroids with a side 
chain having a hydroxyl group similar to the 3α-OH in steroids.40 Steven Mennerick et al. 
reported the steroidal analog (3α,5β)-20-oxo-pregnane-3-carboxylic acid (3α,5βPC), a 
neuroactive steroid that positively modulates the GABAA receptor at low concentrations 
and negatively modulates NMDA receptors.39  
 
Figure 9. Benz[e]indenes and selective antagonists of neurosteroids. 
The number of binding sites and their positions in GABAA receptors is unclear. 
Thus, it is hard to understand the mechanism of action of neurosteroids at GABA receptors 
without any knowledge of their binding sites. Evidence of multiple distinct neurosteroid 
binding sites at GABA receptors was reported recently.41-42 The action of neurosteroids at 
GABA receptors by using steroidal antagonists has been studied. These examinations 
showed that 3β-hydroxysteroids competitively (non-competitively in electrophysiological 
studies) antagonize the activities of both of the potentiating steroids allopregnanolone (5α-
reduced) and pregnanolone (5β-reduced). Mennerick et al also reported the synthesis and 
actions of (3α,5α)-17-phenylandrost-16-en-3-ol (17PA), a selective antagonist of 
neurosteroid potentiation at GABA receptors. Studies on 17PA provided further evidence 
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for the presence of multiple neurosteroid binding sites.41 The compound 17PA antagonized 
anesthetic actions and direct gating of GABAA receptor channels by 5α-reduced steroids, 
but showed little or no effect on 5β-reduced steroids as well as little effect on barbiturate 
and benzodiazepine potentiation. Also 17PA showed a competitive interaction with 
steroids by decreasing inhibition of 5α-reduced steroid potentiation when steroid 
concentration increased.42 
1.1.6 Anticancer and some biologically active heterosteroids  
Cortistatins are a group of natural steroids, isolated from the marine sponge 
Corticium simplex in 2006.43 Cortistatin A is the most potent compound that inhibits 
proliferation of human umbilical vein endothelial cells (HUVECs) and displays selective 
inhibition of CDK8 and CDK19 kinases, which is key for angiogenesis and wet macular 
degeneration.44-45 In 2006, E. J. Corey et al. synthesized structurally simple but biologically 
active analogs of cortistatin A (Figure 10).45 On the basis of the biological data reported on 
various cortistatins, they synthesized analogs 1&2 which show greater inhibitory activity 
in the process related to angiogenesis than natural Cortistatins. They also made many 
changes in cortistatin analogs by varying the heterocycle at the C-17 position and some of 
them showed greater activity than Cortistatin.  
 
Figure 10. Anticancer and some of the biologically active azasteroids. 
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 Danazol and Stanozolol are synthetic steroidal compounds similar to testosterone 
in their structures (Figure 11). Danazol is a derivative of ethisterone where the keto group 
is replaced with an isoxozol moiety. Synthesized in 1963, and it is used for the treatment 
of endometriosis and some other congenital diseases.46-47 Danazol has complex 
pharmacology which includes inhibition of enzymes involved in steroidogenesis and 
activation of sex hormone receptors.47 Stanozolol is an anabolic steroid synthesized from 
dihydrotestosterone by replacing the keto group with a pyrazole ring.48 Stanazolol is used 
in the treatment of anemia in humans and for the promotion of muscle growth in other 
animals.49 Besides its legitimate medical usage, stanozolol is one of the widely used 
performance enhancing drugs.50 
 
Figure 11. Structure of danazol and stanozolol. 
Abiraterone and Cardenolides are also similar to Cortistatin analogs in their 
structures (Figure 12). Abiraterone is a steroidal anti-androgen and it is a successful drug 
which is used in the treatment of prostate cancer.51-52 It has also been tested in the treatment 
of advanced estrogen-dependent breast cancer.53 Abiraterone inhibits the synthesis of 
testosterone by blocking an enzyme called cytochrome P17. Cardenolides are unique 
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steroidal toxins produced by many plants such as those in the family Apocynaceae. These 
are heart arresting natural steroids that act by inhibiting the enzyme Na/K -ATPase.54-55  
 
Figure 12. Structures of Abiraterone and cardinolides. 
Bufadienolides are toxic natural steroidal compounds homologues to Cardenolides (Figure 
12). In addition to their occurrence in certain toads, the plant families Crassulaceae and 
Hyacinthaceae are also rich sources of bufadienolides. This class of compounds is 
generally used in traditional remedies for the treatment of infections, inflammation, and 
disorders associated with the central nervous system.56 
Several other biologically effective 17-heteroaryl limonoids (such as azadirone, 
azadiradione, and gedunin), are structurally related to Abiraterone, isolated from the neem 
tree, Azadirachta indicia, a native Indian subcontinent tree that is cultivated throughout the 
tropics (Figure 13).57-58  Azadirachta indicia belongs to the Meliaceae family, which is 
known for triterpene derivatives having several pharmacological activities including 
antifeedant, antibacterial, antifungal, antimalarial, antipyretic and growth regulatory 
properties. Cytotoxicity and anti HIV properties of limonoid constituents of Meliaceae 
were also reported recently.59 These tree species are well known for their tremendous 
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therapeutic properties and used to treat more than 40 maladies. Various parts of the tree 
(stem, oil, seed, bark, leaf) have been used in ayurveda, unani, and homeopathic 
medicine.57-61  
 
Figure 13. Examples of 17-heteroaryl linonoids. 
The studies in vitro and in vivo of azadirone and its derivatives, isolated from neem 
flowers, identified such compounds as cytotoxic agents and it is concluded that the furan 
moiety present in azadirone is one of the structural requirements for its cytotoxic activity.59 
Another study on azadirone revealed its anti-cancer/anti-tumor properties and its 
mechanism of action on human tumor cells that are resistant to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). The combination of TRAIL and azadirone is 
may be an effective in anticancer treatment.57-58 Azadiradione is another potential 
therapeutic compound isolated and studied in vivo in various ulcer models which showed 
strong antiulcer activity by inhibiting the proton pump with its cytoprotective and 
antisecretory effects.60 Azadiradione and its companion, gedunin, are effective as (HPA) 
human pancreatic α-amylase inhibitors (anti-diabetic).57  
Various compounds of another class of triterpenoids, including KHF16 (24-
acetylisodahurinol-3-O-β-D-xylopyranoside), extracted from the medicinal plant 
Cimicifuga foetida, have been reported to possess anticancer properties by inducing cell 
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cycle arrest and apoptosis (Figure 14).62 Triple-negative breast cancer (TNBC) is one 
subtype of breast cancer that is promoted by HER2 protein. Apoptosis inhibits the 
development of cancer, but unfortunately, the drugs used for TNBC cancer indirectly 
stimulate the generation of anti-apoptotic proteins by improper regulation and activation 
of NF-KB, a protein that controls cell survival.
62-64 Natural compounds obtained from plants 
including Cimicifuga recemosa are another option for cancer treatment. The compounds 
cucurbitacin E and KHF16 showed inhibition of higher levels of anti-apoptotic proteins 
such as Mcl-1 and, promoted survival by regulating NF-KB activation.
62-64  
 
Figure 14. Structures of triterpenoids, KHF16 and cucurbitacin E. 
 
Figure 15. Anticancer compounds isolated from Cimicifuga. 
Previously, many triterpenoid glycosides similar to KHF16 (including cimigenol 
and its derivatives) (Figure 15) were isolated from the aforementioned herb Cimicifuga 
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recemosa. These compounds were tested for cancer chemoprevention in vitro.65 Cimigenol 
and its derivative cimigenol-3,15-dione showed significant antitumor activity in an animal 
model of two stage skin tumor carcinogenesis. 
Olesoxime (cholest-4-ene-3-one oxime) is a cholesterol-oxime with 
neuroprotective and neuroregenerative properties (Figure 16). It was first identified for 
promoting motor neuron survival in cultured rat neurons in the absence of neurotrophic 
factors.66 Olesoxime binds to the outer mitochondrial membrane proteins and hinders 
oxidative stress-mediated permeability transition pore (mptp) opening. It is a potential 
therapeutic drug (development started in 2015) for treating neurodegenerative/motor 
neuron diseases involving trophic factor deprivation and mitochondrial dysfunction such 
as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).67 It is 
hypothesized that olesoxime may be clinically useful in treating autism because this disease 
is also related to mitochondrial dysfunction and mptp opening mediated by oxidative 
stress.68 Huntington’s disease (HD) is another neurodegenerative condition involving 
mitochondrial dysfunction. Recent research with olesoxime in animal models show 
promising results and support its further study in the treatment of HD.69-70  
 
Figure 16. Chemical structure the drug olesoxime. 
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Cephalostatins are disteroidal pyrazines which show cytotoxicity against human 
tumors (∼1 nM in the 2-day NCI 60 cell panel) (Figure 17). They are among the most 
potent anticancer agents known by oncologists.71 Isolation of Cephalostatins was reported 
in 1988 from the marine tubeworm Cephalodiscus gilchristi.72 To date Cephalostatin 1 is 
the most powerful anticancer agents ever tested. All Cephalostatins have two steroidal 
skeletal units linked by a pyrazine ring. Cephalostatin 5 and 6 are unusual among all others 
in this family in that they bear aromatic C-rings while retaining significant cell growth 
inhibition.  
 
Figure 17. Structures of antitumor cephalostatin series. 
1.1.7 Non-steroid steroidal mimics  
Anabolic steroids are compounds that are similar to androgens (such as 
testosterone) in structural and biological properties. The mechanism of action of anabolic 
steroids begins when the compound binds to an androgen receptor. A novel class of 
androgen receptor drugs called Selective Androgen Receptor Modulators (SARMs) has 
been developed to minimize adverse effects of anabolic steroids on such targets as the 
prostate and heart.20 Among all SARMs, the non-steroidal SARMs are drawing tremendous 
 20 
 
attention since the first report of such compounds in 1998, as the use of anabolic steroids 
is limited by lack of tissue selectivity and prostate impairment.73 Many of the in vivo 
clinical properties of non-steroidal SARMs have been reported.20, 73-75 These compounds 
show therapeutic activities such as the counteracting of muscle wasting associated with 
burns, cancer, end-stage renal disease, osteoporosis, frailty, or hypogonadism. Certain 
SARMs are aryl-propionamide (Ostarine, Enobosarm or GTx-024), bicyclic hydantoin 
(BMS-564,929), quinolinones (LGD-4033), tetrahydroquinoline analogs (S-40503) and 
some other imidazole, indole, and pyrazoline derivaties.  
 
Figure 18. Non-steroidal selective androgen receptor modulators. 
Apart from the androgens and SARMs, there are several other therapeutic non-
steroid steroidal mimics such as non-steroidal estrogens and Selective Estrogen Receptor 
Modulators (SERMs) that have been using as drugs for hormone related complications.75  
These compounds interact with estrogen receptors selectively in target cells as estrogen 
receptors vary in their structure within different tissues such as breast, bones, and uterus. 
Selective androgen receptor modulators are the most well-studied and most used drugs for 
the treatment of postmenopausal related issues including breast cancer and osteoporosis. 
Non-steroidal estrogens like Stilbestrol and its derivatives are used for the treatment of 
estrogen deficiency, menopausal symptoms, and prostate cancer.76 The drugs such as those 
with a triphenylethylene group (Clomifene, Tamoxifen, Toremifene and Ospemifene), 
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Raloxifene, and newly discovered SERMs such as lasofoxifene, bazedoxifene and 
arzoxifene, are the examples in this class.  
 
Figure 19. Non-steroidal selective estrogen receptor modulators. 
1.2 Previous synthetic efforts reported on azasteroids 
 Heterosteroids, particularly azasteroids, are of interest as novel drugs and the 
challenges in their synthesis prompted synthetic chemists to initiate studies in the total or 
partial synthesis of these compounds. Most of the synthetic approaches performed on 
azasteroids followed ring contraction and expansion strategies by using oxidative 
cleavages or Beckmann rearrangements.22-24,77-81 The direct synthetic methods leading to 
the azasteroids are very limited. Mentioned here are some of the previous partial/total 
synthetic methods leading to azasteroids including ring opening strategies in order to 
introduce nitrogen atoms.  
1.2.1 Ring contraction-expansion strategy by using Beckmann rearrangement 
 In order to develop a route for the synthesis of 2-azasteroid 9, Robinson et al.23 
used a ring contraction-expansion strategy starting from epiandrosterone 4 (Scheme 1). 
Initially, the A-ring was cleaved using chromium trioxide in acetic acid to get dicarboxylic 
acid compound 5. The seven-membered anhydride compound 6 was obtained from the 
corresponding dicarboxylic acid by reduction followed by acetylation. The decomposition 
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of anhydride 6 at high temperature yielded A-norandrosterone 7. The keto group on the 
five membered ring was converted into a mixture of oximes 8 followed by Beckmann 
rearrangement to produce azasteroid 9.  
 
Scheme 1: Ring contraction and expansion strategy in azasteroidal synthesis. 
1.2.2 Ring opening and closing strategy by using oxidative cleavage 
The opening of a steroidal ring by oxidative cleavage to introduce a nitrogen atom 
is one of the commonly used method in azasteroidal synthesis. As previously mentioned, 
novel azasteroidal selective androgen receptor modulators 12-14 were synthesized by 
Mitchell et al.22 using oxidative cleavage to insert a nitrogen atom at the 4-position, starting 
from testosterone. The azasteroid 12 was obtained in two steps via oxidative cleavage of 
the A-ring of testosterone 10 with KMnO4 followed by treatment with methylamine in 
ethylene glycol with subsequent platinum catalyzed hydrogenation. The formed 
azasteroidal intermediate 12 was converted into other azasteroidal derivatives 13&14. 
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Scheme 2: Ring opening and closing strategy in azasteroidal synthesis. 
1.2.3 A combinatorial one step approach  
 Ma et al.82 described a bimolecular cyclization reaction between two bis-allenes in 
presence of a Rh[I] catalyst to synthesize 2-aza and 2,16-diazasteroids, a combinatorial one 
step approach (Scheme 3). In the reaction they were able to synthesize four steroid like 
products 17-20 in moderate yields started with two different bis allens 15&16 with at least 
one hetero atom as tether in presence of the catalyst trans-[RhCl(CO)(PPh3)2] complex.  
 
Scheme 3: One step approach in azasteroidal synthesis. 
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This combinatorial one step approach is the most efficient method in the synthesis of 
particular azasteroids. However, the starting materials (15 & 16) are not commercially 
available and two steps are needed to synthesize each compound.83-84 Moreover, no 
biological properties have been reported so far for these synthesized azasteroids and 
missing functionality at C-17 could be a major disadvantage.  
1.2.4 Intramolecular Diels-alder strategy 
 Intramolecular Diels-alder and cyclization strategies are excessively used synthetic 
methods in the synthesis of azasteroids as they form cyclic ring structures needed for the 
steroidal backbone. Recently, Ibrahim-Quali et al. reported two different reaction schemes 
(4&5) for the synthesis of 3-azasteroidal type compounds involving a Diels-alder 
cyclization approach.6, 85  
  
Scheme 4: Intramolecular Diels-alder strategy-1 in azasteroidal synthesis. 
In both cases, they used intramolecular Diels-Alder cycloaddition of o-quinodimethanes as 
a key step to synthesize 3-aza-11-thia and 3,11-diaza-1,3,5-trieno steroids. These reactions 
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start with epoxide compound 23, which is obtained from BISTRO 21 and chloroacetic 
anhydride 22 in two steps. The opening of the expoxide with potassium thioacetate which 
is followed by conversion to the intermediary thiol. The thiol was treated with 3-aza-1,3,5-
triene compound 25 followed by thermolysis to the 3-aza-11-thia-1,3,5-trieno steroids 
27&28 (scheme 4). A similar methodology was applied in a second strategy to make 3,11-
diaza-1,3,5-trieno steroids 33&34 (scheme 5). 
  
Scheme 5: Intramolecular Diels-alder strategy-2 in azasteroidal synthesis 
1.2.5 Electrocylization involving Stille and Heck coupling  
 Sunnemann et al. synthesized azasteroidal compounds by using Stille and Heck 
coupling as key steps (Scheme 6).86-87 Stille coupling on bromoenol triflates 36, obtained 
from bromopiperidinones 35, with bicycloalkenylstannanes 37 in presence of Pd and Cu 
catalysts yielded the intermediate compound 38. Compound 38 is then immediately 
coupled with t-butyl acrylate by using a modified Heck coupling. Upon heating the formed 
product 39, involved in an electrocyclization led to steroidal compound 40. The unstable 
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steroids formed during electrocyclization further rearranged on heating to stable steroids 
41.   
  
Scheme 6: Electrocyclization strategy in azasteroidal synthesis. 
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CHAPTER 2: SYNTHESIS OF AZASTEROIDS  
2.1 Design and synthesis of azasteroids 
The purpose of this research was to design various novel azasteroids with concise 
synthetic routes to such compounds. The challenges in the synthesis of steroids, 
particularly azasteroids, and the potential of azasteroids as novel drugs has prompted 
numerous investigations in the synthesis of azasteroids. The synthetic methods leading to 
steroidal derivatives (azasteroids) with one or more nitrogen atoms are very limited. 
Generally, oxidative cleavage of the steroidal rings is needed to introduce nitrogen atom(s) 
to synthesize azasteroids.22, 77 Even though several azasteroidal synthesis have been 
reported, there is still a need for the development of new methodologies as the previous 
synthetic methods are limited to particular steroidal structures. Preparation of novel 
azasteroidal compounds and the modification of substituents on their steroidal skeletons 
might provide congeners with useful biological properties. 
  
Scheme 7: Synthesis of tricyclic benz[e]indenedione (Dimer, 46). 
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 Anhydrobases, a class of heterocyclic compounds, are known for their extreme 
instability.88-89 With the intent of exploring interesting reactivities of anhydrobases, Becker 
et al. synthesized and examined the chemistry of anhydrobases in the isoxazole series 
because of their weak nitrogen-oxygen bond.89 A facile process involving commercially 
available starting materials such as 3,5-dimethylisoxazole 42 and carbocyclic vinylogous 
ester 43 led to the enone product 44 which was subsequently converted into the 
corresponding oxocycloalkenyl isoxazolium anhydrobase 45. Specifically, the lithiation of 
3,5-dimethylisoxazole 42 with nBLi in THF at -78 °C was performed by following the 
Micetich method90-91 that allows the lithiated intermediate to participate in a nucleophilic 
reaction by addition of 3-ethoxy-2-cyclohexen-1-one 43. After acidification of the reaction 
mixture with 2N HCl, the corresponding enone 44 was obtained in good yield. The N-
alkylation of enone 44 with trimethyloxonium tetrafluoroborate followed by deprotonation 
with addition of a solution of n-BuLi in THF at -78 °C afforded the desired anhydrobase 
45. It has been observed that a new tricyclic benz[e]indenedione 46, a compound produced 
via initial dimerization of the anhydrobase, was formed when warming 45 in benzene at 50 
°C.  
The structure of dimer compound 46 caused us to speculate on plans for synthetic 
routes to new steroid congeners, particularly azasteroids with potential biological activity. 
We were especially intrigued by the fact that the tricyclic ring structure and the keto 
functional group next to the aromatic ring provides a platform to establish a new six 
membered A-ring (or a mimic there of) needed for a steroidal skeleton. Moreover, the 
dimer compound 46 is equipped with interesting functionality at C-17 along with never 
before explored vinylogous amide functionality at C-15 and C-16.  Here, we planned to 
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synthesize a novel 1, 2-diazasteroid (pyridazinone) 47 and the azasteroidal mimic 
compounds 48 and 49. The triazole moiety in 48 and furazan moiety in 49 were expected 
to align in the position of the A-ring, as a result of steric repulsion with the methyl group 
present on the aromatic C-ring, thus providing overall correspondence to a tetracyclic 
steroid skeleton. 
 
Figure 20. Structures of novel azasteroid and azasteroidal mimics. 
2.1.1 One-pot pyridazinone formation method from ketones  
 There are many reported one-pot methods for the synthesis of pyridazinone 
molecules from ketones (acetophenone, 1-tetralone).92-96 Similar methodology could, in 
theory, be used to develop a new ring on dimer 46. An attempt to make a new ring was first 
performed on a model compound, 1-tetralone 50, which is similar to the moiety that is 
present in the dimer molecule (Scheme 8). Installment of the new ring on 1-tetralone was 
achieved by treating with glyoxylic acid in acidic medium at 110 °C, followed by treatment 
with hydrazine hydrate at 120 °C in one pot. However, the same chemistry failed on 
compound 46. The reaction of glyoxylic acid at the α-position of the benzylic ketone 
moiety was also not observed when the reaction was performed in two steps.  
With these results we postulate that the reaction failed because of the weak 
nucleophilicity or inefficient enolization of the ketone required for the desired aldol 
 30 
 
condensation. To increase the electrophilicity of the aldol partner, we made a second 
attempt using a reactive keto reagent, diethyl ketomalonate, at 100 °C for 12h (Scheme 9).  
 
Scheme 8: Pyridazinone formation reaction on 1-tetralone and dimer. 
 
Scheme 9: Second attempt of making Pyridazinone on dimer. 
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A subsequent closing of the ring using hydrazine hydrate was hypothesized. Similar results 
were obtained such that it was successful on 1-tetralone but not on the desired dimer 
compound 46. According to proton NMR data it has been assumed that the diethyl 
ketomalonate was reacting with the vinylogous amide instead of with the benzylic ketone. 
More data are needed to confirm the structure of the product.  
2.1.2 Hydrazone formation methods 
 After difficulties with the aldol reactions, the focus shifted towards the reactivity 
of the benzylic ketone moiety. Hydrazone formation is one of the feasible reactions that 
takes place readily on ketones.97-98 Such a strategy was tried using a substituted hydrazine 
as a reagent with an appropriate side chain (such as aminoguanidine and 
cyanoacetohydrazide) needed for ring closure. Two reactions were performed on 1-
tetralone by using aminoguanidine97 and cyanoacetohydrazide98 with a subsequent plan of 
closing the ring (Scheme 10).  
 
Scheme 10: Hydrozone formations on 1-tetralone. 
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Protic solvents were used in both cases and the products formed in good yields. Piperidine 
was used as catalyst in the second reaction with cyanoacetohydrazide. Unfortunately these 
reactions were not successful on dimer compound even with excess quantity of reagents. 
The reactions might have taken place preferentially at the enone functionality. 
 
Scheme 11: Hydrazone formation attempts on dimer. 
2.1.3 Attempts to activate the benzylic ketone moiety 
The results from previous reactions revealed that the α-position of the benzylic 
ketone or the ketone itself is a poor reactive site. The poor reactivity of this carbonyl group 
is not surprising because of steric interactions with the methyl group present on the 
neighboring aromatic ring.  It was decided to try reactions that can improve the reactivity 
of the ketone and its α-position. Neber rearrangement is one of those organic reactions that 
can activate the α-position of ketones by converting the corresponding oximes into α-amino 
ketones and α-amino acetals.179 For our purposes, the acetal group is required to close the 
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ring with the chain that is formed after reacting the α-amino group with ethyl oxamate.  In 
model studies, 1-tetralone was successfully converted into the corresponding tosylated 
oxime 65 that is needed for the rearrangement, with excellent yields in two steps (Scheme 
12).99-100 However, Neber rearrangement was not attempted on 46 since the model studies 
employing 1-tetralone failed to give any of the desired rearrangement product. 
 
Scheme 12: Neber rearrangement on 1-tetralone. 
2.1.4 Attempted synthesis of compound 49 
A model reaction was performed on 1-tetralone in order to find conditions that 
might be used for preparing compound 49. Thus, the addition reaction between 1-tetralone 
and lithiated 3,4-dimethylfurazan 69 with subsequent dehydration in presence of acidic 
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acid was explored (Scheme 13). The method failed in the initial stages as the alkylation 
reaction was not produced the corresponding alcohol product 70.  
 
Scheme 13: An alkylation reaction on 1-tetralone. 
 
Scheme 14: Horner-Wadsworth-Emmons reaction on 1-tetralone. 
The Horner- Wadsworth – Emmons strategy was also investigated to convert 1-
tetralone into the corresponding olefin. The first step, which is the making of phosphorous 
ylide 72 was successfully performed (45% yield) by treating lithiated 3,4-dimethylfurazan 
with diethylchlorophosphate (Scheme 14). The obtained phosphonate was then converted 
into the corresponding phosphonate stabilized carbanion by treatment with n-BuLi, which 
was then allowed to react with 1-tetralone. The strategy failed to generate the desired 
product.   
The reason behind the above failed reactions was that 1-tetralone is too readily 
enolized, thus precluding nucleophilic additions to the keto group.101 Interestingly, a 
reaction took place at the α-position of 1-tetralone when it was treated with n-BuLi 
followed by diethyl ketomalonate (Scheme 15).  
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Scheme 15: Enolization reaction of 1-tetralone. 
2.1.5 Hydrazone formation using 4-amino-4H-1,2,4-triazole 
After failures in the formation of tetralone hydrazones with compound 46, it was 
decided to fully explore perfect conditions for this reaction on 1-tetralone using various 
reaction conditions. Further trials were started that were directed toward the synthesis of 
the second target molecule 48 as the synthesis of 48 involves the formation of a hydrazone 
from dimer 46. The hydrazonation reaction on 1-tetralone was investigated using 4-amino-
4H-1,2,4-triazole 73 under several conditions (Scheme 16), especially in different solvents 
at various temperatures. The results are summarized in Table 1.  The yield was very low in 
alcohols and some other organic solvents such as benzene, toluene and pyridine (entries 1-
5).  In contrast, the yields were moderate with the addition of catalysts (BaO, TsOH)(entries 
6&7). Heating at high temperature without any solvent or in isoquinoline as well as stirring 
in acetic acid provided good yields (entries 8-10). In all cases, 4 A° molecular sieves were 
used to maintain dry conditions. 
 
Scheme 16: Hydrazone formation employing 4-amino-4H-1,2,4-triazole moiety on 1-
tetralone. 
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Entry Solvent Catalyst Temp °C Yield % (74) 
1 EtOH H+ 70 15 
2 Et3N - 80 20 
3 Benzene - 80 16 
4 Toluene - 100 26 
5 Pyridine - 100 22 
6 EtOH BaO 25 48 
7 Toluene TsOH 100 50 
8 AcOH - 25 72 
9 - - 100 83 
10 Isoquinoline - 150 85 
 
Table 1. Reaction conditions and yields for the hydrazonation of 1-tetralone with 4-
amino-4H-1,2,4-triazole. 
 
Thus, the high yielding reaction conditions (such as acetic acid as a solvent, 
isoquinoline at 150 °C, and without solvent at 100 °C) were applied to dimer 46 (Scheme 
17). In all cases, the hydrazone formation was observed to occur at the cyclohexenone 
carbonyl with both stereo isomers present (E and Z of 75) in a 3:1 ratio. No hydrazone 
formation at the benzylic ketone of 46 took place even with an excess of 4-amino-4H-1,2,4-
triazole.  
These failed hydrazonation attempts demonstrated that the benzylic ketone is under 
the steric influence of the methyl group of the aromatic ring. The effect of steric hindrance 
of methyl group on adjacent carbonyl carbon was then confirmed by conducting a model 
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study with 5,8-dimethyl-1-tetralone 77 which yielded no product when treated with 4-
amino-4H-1,2,4-triazole (Scheme 18), in contrast, the same reaction was successful with 
1-tetralone.  
 
Scheme 17: Hydrazone formation attempts using 4-amino-4H-1,2,4-triazole on dimer. 
 
Scheme 18: Attempted hydrazone formation between 5,8-dimethyl-1-tetralone and 4-
amino-4H-1,2,4-triazole. 
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From the above results, it has been concluded that the benzylic ketone is not as 
reactive as expected and that the aromatic ring is not providing any additional advantage. 
There are some other reactive sites on dimer 46 such as the cyclohexenone, the enaminone, 
and the tertiary benzylic hydrogen present on the five membered ring. We can presume 
that the reason behind the poor reactivity of this benzylic ketone is because it is located on 
the tricyclic rigid structure, and primarily, that is under the steric hindrance of the methyl 
group present on the aromatic ring (Figure 1).  
 
Figure 21. Reactive and hindered moieties on dimer 46. 
2.1.6 Hydrazone formation catalyzed by Sc(OTf)3 
To increase the reactivity of the benzylic ketone, the hydrazone formation reaction 
has been carried out on 5,8-dimethyl-1-tetralone in the presence of ketone activating 
catalysts such as titanium isopropoxide, cerium(III) chloride and scandium triflate. Of these 
catalysts, scandium triflate showed promising results when 5,8-dimethyl-1-tetralone and 
4-amino-4H-1,2,4-triazole were heated at 100 °C in the presence of 15 mole percent of 
scandium triflate without any solvent for 3h, 40% yield of the corresponding hydrazone 
was obtained (Scheme 19).   
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Scheme 19: Scandium triflate catalyzed hydrazonation of 5,8-dimethyl-1-tetralone. 
The same reaction conditions were applied to dimer 46 and it has been observed 
that the triazole reacted with both ketones yielding 30% of monohydrazone product (75) 
(reacting at cyclohexenone carbonyl) and nearly the same percent of bishydrazone product 
(76) (reacting at both keto groups) (Scheme 20).  
 
Scheme 20: Hydrazone formation on dimer in presence of catalyst. 
Geometric hydrazone isomers were observed in the NMR data for both products. Similar 
results were obtained when the reaction was performed in the absence of catalyst for one 
hour (converting dimer compound into monohydrazone) and stirred in presence of catalyst 
for another 2h in one pot. Some improvement in yield of bishydrazone product was 
observed when the reaction was carried out in two steps (Scheme 21). Thus, a 75 % yield 
of monohydrazone product was realized in the first reaction without catalyst. The 
monohydrazone is then reacted with the triazole reagent in the presence of scandium triflate 
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to afford 40% yield of the bishydrazone product along with 20% of unreacted starting 
material. 
 
Scheme 21: Hydrazone formation (two steps) on dimer in presence of catalyst. 
The facile formation of the monohydrazone product in the presence/absence of 
catalyst showed the higher reactivity and availability of the cyclohexenone carbonyl. 
Similar selectivity was expected and observed when a dehydrazonation reaction was 
performed on bishydrazone 76. Thus, treatment of bis-hydrazone 75 in THF with 
CuCl2/H2O solution over 10h at rt yielded the desired monohydrazone 48 (Scheme 22).
102 
It is gratifying to confirm that the selective dehydrazonation occurs on the cyclohexenone 
hydrazone and leaves the benzylic hydrazone unaffected. Moreover, importantly, it is not 
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surprising that we identified only one isomer in the product by using H1- NMR 
spectroscopy, indicating that the initial hydrazone formation took place stereoselectively 
on the benzylic ketone as expected (directed away from the methyl group present on the 
aromatic ring). 
  
Scheme 22: Selective dehydrazone reaction on Bishydrazone compound 76. 
With the novel steroid mimic 48 now in hand, we are eager to ascertain if it possesses 
interesting biological properties. We also intend to pursue purification of both 
enantiomers via chiral HPLC in the near future.  
2.2 Conclusion regarding azasteroidal synthesis 
 Natural and synthetic steroids are very important in chemistry as well as in 
medicinal biology. Steroids have tremendous therapeutic properties including anti-
inflammatory, growth stimulation and also used as oral contraceptives. Steroids and their 
biological properties can widely vary in the configuration of gonane (steroidal nucleus) 
and the nature/position of attached groups. We can produce significant differences in their 
biological properties by making modifications in steroidal molecular structure.  
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Figure 22. Secosteroids. 
Among those three compounds (75, 76 and 48) obtained from hydrazone reactions, 
compound 48 grasping most of our attention as it is a mimic of azasteroidal molecular 
structure. However, the other two compounds also have a salient feature of secosteroidal 
structure. The steroidal compounds with broken ring structure are classified as 
secosteroids. These are similar to the non-steroidal compounds in their physical appearance 
but having steroidal biological properties. Cholecalciferol (vitamin D3) and 
diethylstilbestrol are good examples of known secosteroids.  It is hypothesized that these 
compounds mimic the molecular structures of steroids with formation of rings by virtual 
bonding.  
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PSEUDO AZULENYL NITRONES 
CHAPTER 3: INTRODUCTION 
3.1 Free radicals in biological systems 
Atoms, molecules or ionic species which possess one or more unpaired electrons 
are called free radicals. The species of free radicals containing oxygen or nitrogen atoms 
in which the unpaired electron resides on the oxygen or nitrogen are referred to as reactive 
oxygen species (ROS) or reactive nitrogen species (RNS), respectively. The concept of 
free radicals was discovered and identified many decades ago.103-105 However, the 
importance of free radicals in physiological functions and their role in biological disorders 
have been explored only in the last few decades.106  
Free radicals such as ROS and RNS are generated during cellular metabolism. They 
can be either harmful or beneficial to the biological system.107 At low or moderate 
concentration, they play an important beneficial role in mediating cellular signaling (as a 
part of the body’s defense mechanism), and in various physiological functions.108  The 
biological damages referred to oxidative stress and nitrosative stress are a harmful hallmark 
of the free radical generation.109-111 The adverse effects can occur by either a massive 
production of ROS and RNS radicals or by the deficiency of enzymatic and non-enzymatic 
antioxidants in living organisms. The ROS radicals are highly reactive species and create 
oxidative stress by damaging vital biological molecules such as lipids, nucleic acids, DNA, 
carbohydrates and proteins. Overproduction of ROS radicals is deleterious and leads to 
oxidative stress which is responsible for many pathological conditions such as cancer, 
aging, stroke, cardiovascular pathology and many neurodegenerative diseases.104, 112-116 
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Hydroxide radical (OH), superoxide anion radical (O2-), and nitric oxide radical (NO) 
are some examples of ROS. Some other non-radical compounds, generated from ROS 
radicals, such as hydrogen peroxide (H2O2) and peroxynitrite ion are also harmful.  
3.1.1 Generation of reactive oxygen species (ROS) in the human body 
The genesis of free radicals occurs either through external sources such as x-rays, 
UV-rays, smoking, pollution and industrial chemicals, or by normal metabolic enzymatic 
or non-enzymatic processes. The ROS radicals are the most important radicals among all 
free radicals generated in living systems. Superoxide radical or superoxide anion radical is 
treated as a primary ROS radical, which is produced by either metabolic processes or by 
reduction of molecular oxygen via photochemical reactions. Superoxide radical itself is not 
a dangerous ROS radical but it further interacts with other molecules in order to give rise 
to harmful secondary ROS radicals and non-radical compounds.  
3.1.2 Superoxide radical anion 
Mitochondria are the main source of superoxide radicals.117 Adenosine triphosphate 
(ATP) synthesis is an enzymatic and respiratory biological process that occurs inside the 
mitochondria. The co-enzyme nicotinamide adenine dinucleotide ‘NADH’ produced in 
glycolysis is responsible for the formation of electrons at mitochondria via redox reactions. 
These generated electrons participate in the electron transport chain through a series of 
transition molecules, such as coenzymes, cytochrome to generate ATP (Figure 23). 
Oxygen, at the terminus of the electron transport chain, serves as a natural terminator of 
these free radical reactions by reducing itself into water. The enzymatic process is kept 
under control by physical and chemical couplings of the intermediates. 
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Every time an electron goes from a higher energy state to a lower energy state over the 
course of this electron transport chain, it releases energy. The released energy is used to 
pump protons across the inner membrane of the mitochondria.118 Because of the pumping 
of protons from the inner membrane (matrix) to the outer membrane of the mitochondria, 
the matrix or inner membrane becomes slightly nucleophilic. 
 
Figure 23. Electron transport chain 
On the other hand, during the electron transport process, a small amount (1-3%) of 
premature electron leakage to molecular oxygen takes place.108 The leaked electrons are 
involved in the generation of deleterious superoxide radicals by a univalent reduction 
reaction with oxygen molecules.  
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 Superoxide radicals are also produced by an enzyme called NADPH oxidase during 
the respiratory burst or oxidative burst, an immune defense mechanism to combat 
infections.119 The NADH or NADPH oxidase is used to reduce molecular oxygen into 
superoxide radical and then H2O2, which are employed in destroying bacteria. Superoxide 
radicals are also generated by another enzyme, xanthine oxidase, which converts 
hypoxanthine to xanthine (then to uric acid).120 In both oxidation reactions, it produces 
superoxide radicals and causes some oxidative damage via oxidative stress. The other 
prominent pathway for generating superoxide radical is the oxidation of NADH in the 
presence of catalase.121 The mechanism involves the conversion of NADH to NAD radical 
by catalase in the presence of hydrogen peroxide. The resulting NAD radical transfers its 
electron to an oxygen molecule in order to produce the superoxide radical. 
 
Several other enzymes producing superoxide radicals have been reported such as 
peroxidases, lipoxygenase122 and cycloxygenase.123 On the other hand, non-enzymatic 
sources of superoxide radicals have also been reported. For example, thiols undergo several 
one electron reactions and produce disulfide radical anions and which are responsible for 
the donation of one electron to an oxygen molecule with the formation of the superoxide 
radical.124 
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3.1.3 Secondary free radicals 
 Superoxide radical itself is not a dangerous ROS radical. However it further 
interacts with other molecules to develop harmful secondary ROS radicals such as 
hydroxyl radicals and peroxyl radicals. Superoxide dismutase (SOD) is an important 
enzyme in the body’s antioxidant defense system that can protect cells from superoxide 
toxicity by converting superoxide into either molecular oxygen molecule or hydrogen 
peroxide.125   
 
Peroxisomes are the major sites where most of oxygen consumption takes place in the cell 
and they participate in several metabolic functions. These oxygen consumption functions 
also produce hydrogen peroxide.126 The vast accumulation of hydrogen peroxide is 
prevented by catalase, present in peroxisomes to maintain a gentle balance of electron 
transport chain. However, the disturbance in balance may happen with leakage of hydrogen 
peroxides taking place when the peroxisomes are damaged. This leakage, in turn, makes a 
significant contribution to oxidative stress.  
Iron and copper are essential metals and they occur throughout the body as central 
molecules in hemoglobin and also involve in protein synthesis. During stress conditions 
involving excess superoxide, free iron is released from iron containing molecules.127 The 
released Fe2+ can participate in a Fenton reaction (7 and 8) with hydrogen peroxide which 
generates the highly reactive hydroxyl radical. The superoxide radical produces the 
hydroxyl radical by involvement in a reaction with hydrogen peroxide called the Haber-
Weiss reaction (9) which contains a Fenton reaction.  
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The hydroxyl radical is the most dangerous radical among ROS as it has very high 
reactivity in vivo (half-life 10-9 S approximately).128 Thus, it reacts instantly with 
macromolecules close to its generation site such as carbohydrates, nucleic acids, amino 
acids, lipids, DNA and proteins. Peroxyl radicals are another type of radicals derived from 
oxygen. Hydroperoxyl radical or perhydroxyl radical is the simplest one among these and 
it is a protonated form of the superoxide radical anion. It has been reported that 
hydroperoxyl radicals may participate in the initiation of fatty acid peroxidation.129  
3.1.4 Reactive nitrogen species (RNS) 
Besides ROS, there is another group of free radicals containing nitrogen as a central 
atom, in which unpaired electron(s) resides on nitrogen, called reactive nitrogen species 
(RNS). Nitric oxide radical (NO) is a significant radical among RNS because of its 
biological importance. It is generated by some tissues via specific nitric oxide synthase in 
order to maintain essential biological and physiological signaling processes including 
defense mechanism, muscle relaxation, neurotransmission, blood pressure and immune 
regulations.130-131 The overproduction of RNS may occur, called nitrosative stress, when 
the production of RNS exceeds the system’s ability to neutralize them.132 Nitrosylation 
reactions are the results of nitrosative stress and these reactions interrupt the functions of 
proteins by making modifications in their structure.  
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Because of instability and a very short half-life, NO may react with superoxide 
radical anion during the oxidative burst and produce the more oxidatively active molecule, 
peroxynitrite anion (ONOO-), which subsequently leads to the generation of hydroxyl and 
nitrogen dioxide radicals. Peroxynitrite anion is capable of oxidizing other molecules and 
may cause lipid oxidation and DNA fragmentation.133  
 
Some oxidants, such as hydrogen peroxide (H2O2), hypochlorous acid (HOCl), nitrous acid 
(HNO2), and dinitrogen trioxide (N2O3) are not free radicals, but easily engender radical 
reactions similar to peroxynitrite anion (ONOO-).134 
3.1.5 The body’s antioxidant defenses 
The generation of free radicals in biological system is inevitable, but the system 
adapted to produce several antioxidant defense mechanisms to reduce their impact. The 
body’s antioxidants are divided into two categories: enzymatic and non-enzymatic. 
Superoxide dismutase (SOD), catalase and glutathione peroxidases are three major 
enzymatic antioxidant processes involved in the direct neutralization of ROS and RNS 
radicals.106 In 1969, McCord and Fridovich discovered an antioxidant enzyme called 
superoxide dismutase (SOD) that acts against superoxide radical anions by converting them 
into hydrogen peroxide and oxygen molecules.135 
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The enzyme catalase is highly efficient in converting hydrogen peroxide molecules into 
water and molecular oxygen. It neutralizes millions of hydrogen peroxide molecules and 
finishes the detoxification process started by SOD. Glutathione peroxidases also reduce 
hydroperoxides similarly to catalase.  
 
Non-enzymatic antioxidants are further divided into metabolic and nutrient antioxidants. 
Metabolic antioxidants such as glutathione, uric acid, lipoid acid, melatonin etc., are the 
endogenous antioxidants produced by metabolism in the body and nutrient antioxidants 
such as vitamin E, vitamin C, carotenoids, fatty acids, trace metals etc., are the exogenous 
antioxidants that must be provided through the diet. 
3.1.6 Pathological conditions caused by free radicals 
The role of free radicals does not end up with antioxidants. Excess generation of 
free radicals i.e., an imbalance between the generation and neutralization of ROS radicals 
in biological system creates a pathological condition called oxidative stress.112 Oxidative 
stress is involved in many pathological conditions including cancer, cardiovascular 
diseases, ischemia, ageing, diabetes and several other neurodegenerative disorders.112-116 
Free radicals produced in mitochondria create ‘mitochondrial oxidative stress’ that is an 
indication of a pro-oxidative shift in the plasma thiol/disulfide redox state which impairs 
glucose tolerance. Cancer and diabetes are the typical pathological conditions observed 
during mitochondrial oxidative stress.136-137 The process of aging is an enduring damage 
developed by free radical activity on lipids, DNA and proteins.104 Other pathological 
implications involve chronic inflammations and ischemia/reperfusion injury that are 
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characterized by enhanced activity of either NAD(P)H oxidase or xanthine-oxidase and 
inflammatory oxidative stress. 
Low density lipoproteins (LDL, known as bad cholesterol) becomes more 
dangerous when it gets oxidized with ROS radicals, this process is called lipid 
peroxidation.107 Oxidized LDL accumulates on the walls of arteries and encourages the 
accumulation of inflammatory cells, macrophages and platelets. The plaque begins to grow 
thicker and block blood vessels in the brain. The condition of arterial formation of 
blockages is called atherosclerosis. The blockage creates oxidative stress in the brain and 
leads to ischemic stroke. The ROS radicals also damage adjacent vital biological molecules 
such as nucleic acids, proteins, RNA and DNA. Oxidative DNA damage leads to DNA 
lesions and mutations.   
Stroke is the fifth leading cause of mortality in the USA and is one of the major 
causes of death worldwide.112-116 Stroke results from a disturbance in blood supply to the 
brain. There are two types of strokes, ischemic and hemorrhagic stroke. Ischemic stroke is 
due to the lack of blood supply to the brain hindered by particles that impede blood flow. 
It is further divided into two types, thrombotic and embolic stroke, depending on the way 
it occurs. In thrombotic stroke, the blood clot forms within one of the arteries that supplies 
blood to the brain, whereas, the embolic stroke involves a blood clot formed in another 
location of the body, usually in heart, that travels to the brain until it block a brain vessel. 
As a result of the lack of blood supply to that particular part of the brain, cells start dying 
and eventually the ischemic tissue becomes necrotic. The other type of stroke, hemorrhagic 
stroke, occurs when the blood vessels in a part of the brain accidentally burst and bleed in 
and around the brain. It creates swelling and pressure around the cells and damages brain 
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tissue. The whole brain or part of the brain stops working because of these blood spills. 
High blood pressure and aged blood vessels may be primary etiological factors in 
hemorrhagic stroke.116 
 After a period of ischemia, reclamation of blood supply to the brain or part of the 
brain causes severe injury rather than restoration of normal functions (reperfusion injury). 
Restoration of blood flow to the ischemic organ is essential in order to prevent irreversible 
cellular injury. Reperfusion may augment tissue damage in excess of that produced by 
ischemia alone.138 The injury after reperfusion of previously viable ischemic tissue is 
described as ischemia-reperfusion injury. Multiple organ dysfunction syndrome or 
systemic inflammatory response syndrome may be the consequences of ischemia-
reperfusion injury, which accounts for a 30-40% mortality rate in humans.139  
Reperfusion of ischemic tissues results in a massive generation of ROS and RNS 
including superoxide anions, hydroxyl radicals, hypochlorous acid, hydrogen peroxide and 
nitric oxide radicals.140 Lack of blood and oxygen supply during ischemia leads to the 
accumulation of metabolic intermediates. During ischemia, cellular ATP is degraded to 
form hypoxanthine and also xanthine dehydrogenase is converted to xanthine oxidase. 
Normally, xanthine dehydrogenase is used to oxidize hypoxanthine into xanthine by using 
nicotinamide adenine dinucleotide as its substrate. Xanthine oxidase uses oxygen, so it is 
unable to process the conversion of hypoxanthine to xanthine as there is no oxygen supply 
to the ischemic tissue, resulting in a growth of excess levels of hypoxanthine. In this state, 
the restoration of oxygen supply results in the conversion of the excess hypoxanthine to 
xanthine by xanthine oxidase leading to the formation of harmful ROS.139 The massive 
increase in radicals destroy the cell’s usual defense system and leads to the uncontrolled 
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oxidation of vital biological cell components.141 Inflammation is also responsible for 
injury. The white blood cells generate inflammatory factors as well as free radicals after 
restoration of blood flow. The restored oxygen inside the cell, damages proteins, DNA and 
finally cell membrane. The cell membrane damage in turn creates more free radicals and 
this relentless ischemic cascade leads to apoptosis.141  
3.2 Tissue plasminogen activator (t-PA) 
Tissue plasminogen activator (t-PA) or recombinant tissue plasminogen activator 
(rt-PA) is a plasminogen activator involved in breakdown of blood clots by catalyzing the 
conversion of plasminogen to plasmin. The only drug that FDA has approved to treat acute 
ischemic stroke (AIS) in selected patients is t-PA. Because of reperfusion injury the use of 
t-PA is restricted to within three hours of ischemia and in the absence of hemorrhagic 
stroke.142-143 
3.3 Edaravone  
Edaravone is a free radical scavenger and neuroprotective agent. It is a lipid soluble 
hydroxyl and peroxy radical scavenger, used clinically for the treatment of ischemic stroke 
within 24 hours of the attack. Edaravone is the only drug in its class in clinical practice.144 
It is marketed in Japan since 2001 by Mitsubishi Pharma Corporation. A few clinical 
studies published on the use of edaravone in combination with thrombolytics such as t-PA 
(for both breakdown of blood clots and free radical scavenger activities) have shown 
promising results.145 There are many clinical trials that need to be performed before 
edaravone becomes approved as a drug for Ischemic stroke in the United States and 
elsewhere in the world. 
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Figure 24. Structure of edaravone. 
3.4 Free radical detection and spin trapping 
Detecting free radicals as targets is very crucial to the study of radical reactions in 
chemistry and biology. The direct or indirect detection of free radicals formed during 
biological processes is very important to analyze and understand the mechanism of 
oxidative damage caused by pathogenic free radicals.146 It is very difficult to understand 
free radical reactions as the formed free radical intermediates are highly unstable and 
cannot be detected directly, even in pure free radical generating chemical systems. For 
instance, the half-life of superoxide anion radical is on the order of tenths of microseconds 
and a few nanoseconds for hydroxyl radical.147 However, a number of methods have been 
developed to detect ROS/RNS radicals but these are often limited by specificity and 
sensitivity.148  
  Among all of those instruments that make identification of radicals possible, 
electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy is 
the most commonly used.148 Only those free radicals with relatively long half-lives can be 
measured by ESR. Thus, it is technically possible to directly detect some free radicals in 
real time, but not in biological systems as the half-lives of those radicals are extremely 
short.146 To overcome these obstacles, varied methods have been tested. Among those 
methods, ESR-spin trapping has been proven the best because the spin trapping converts 
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unstable free radicals into the stable adducts and it allows researchers to identify and 
differentiate the number of free radicals generated during a biological process. The ESR-
spin trapping method offers investigators the opportunity to measure and distinguish the 
major ROS molecules such as hydroxyl and superoxide anion radicals in the biological 
system. Spin trapping is a technique in which the undetectable transient radicals are 
converted into corresponding stable adducts and these adducts can be readily detectable by 
ESR.  The compounds used for this conversion method are called spin traps. Usually, 
nitrosoalkanes, nitrones and sometimes metal complexes such as in case of NO radical 
(Fe2+-N-methyl-D-glucamine dithiocarbamate), are used as spin traps.149  
 
Nitrosoalkanes are not used often because of their toxicity and they generally form 
short-lived oxygen-centered radical adducts.144, 150 Nitrones are the most commonly used 
spin trap as they are more applicable to trap biological free radicals such as superoxide and 
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hydroxyl radicals even though the EPR spectra of the ensuring nitrone spin adducts give 
less structural information than compared to the spin adducts formed from nitrosoalkanes. 
3.4.1 Nitrones 
 Free radicals are extant, but ephemeral, in many chemical reactions as 
intermediates, so they are difficult to characterize and study. Several experiments have 
been conducted and reported in mid-1960’s show that nitrones act as ‘spin traps’ by 
reacting with free radicals to form stable adducts, which can be studied by EPR.151-153 
Shortly after discovering the use of nitrones as spin traps in chemical reactions, they were 
also used to trap free radicals generated in biological systems.154 Nitrones trap short-lived 
free radicals and form more stable spin adducts (nitroxides), which are far more stable than 
the parent radicals. Nitroxide stability is explained by resonance.  
 
The PBN (α-phenyl-N-tert-butyl nitrone) and related nitrones are among the most 
intensively studied compounds for use as free radical scavengers to treat ischemic stroke 
(Figure 25).146 Administration of PBN, after 1h of ischemic stroke, showed promising 
results in rats.146 It reacts mostly with short lived free radicals such as superoxide and 
hydroxyl radicals in high concentrations and has an ability to prevent lipid peroxide 
reactions. Another nitrone, 2, 4-disulfophenyl-N-tert-butylnitrone known as NXY-059 was 
synthesized and passed many stages of clinical trials for acute ischemic stroke. The nitrone, 
NXY-059, has an exceptional capability to trap free radicals and superior neuroprotective 
ability compared to PBN or S-PBN (another derivative of PBN) in an in vitro study. It 
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showed greater promising results among other PBN related nitrones as a protective agent 
in treatment, in view of an expanded time window in stroke model studies.155 
 
Figure 25. PBN and its derivatives. 
 Other than PBN related nitrones, the pyrroline based cyclic nitrones such as 5,5-
dimethyl-1-pyrroline N-oxide (DMPO), 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-
oxide (DEPMPO) and 5-ehoxycarbonyl-5-methyl-1-pyrroline N-oxide (EMPO) are 
another class of commonly used nitrone spin traps. This pyrroline based cyclic nitrones are 
much superior to PBN for the detection of hydroxyl and superoxide anion radicals because 
PBN is more suitable for carbon-centered radicals.146 
DMPO has been used for decades to trap free radicals and it allowed the detection 
of a variety of radicals generated during important biological processes.149 However, a 
major disadvantage of DMPO is that the formed superoxide adduct (DMPO/OOH) 
spontaneously decomposes into hydroxyl adduct (DMPO/OH), and as a result, the 
production of superoxide anion radicals has to be identified via the superoxide dismutase 
inhibition of the formation of DMPO/OH. To overcome this difficulty, DEPMPO is used 
as a spin trap for superoxide radical detection and the formed DEPMPO/OOH adduct is 
stable.156 However, the EPR spectra of the formed DEPMPO adducts is somewhat 
complicated because of additional diastereomers from 31P coupling. These complications 
are mitigated in the case of EMPO, as it is reported that the formed superoxide adduct 
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(EMPO/OOH) is eight times more stable than the corresponding adduct formed from 
DMPO. Also, the EPR spectra of EMPO adducts are less complicated than the spectra of 
DEPMPO adducts 157 but problems with diastereomers of EMPO still exist.  
 
Figure 26. Pyrroline based cyclic nitrones. 
3.4.2 Azulenyl Nitrones 
Naturally occurring azulenes (azulene, guiazulene, lactaroviolin) are reported to 
possess some therapeutic properties (Figure 27).158 In 1996, Becker et al.159 synthesized 
AZN (azulenyl nitrone), a new class of nitrone, from naturally occurring guiazulene 
(obtained from the wood of Guaiacum officinale).159  
 
Figure 27. Azulenes and azulenyl nitrones. 
Various biological studies of AZN in animal models showed beneficial properties against 
neurodegenerative diseases.160-162 The oxidation potential of AZN is quite low (0.84 V vs. 
SCE) compared to the oxidation potential of PBN and its derivatives (>1 V). Researchers 
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mainly focused on the synthesis of lower oxidation potential nitrones because previous 
studies showed that antioxidants with low oxidation potentials have greater trapping ability 
for free radicals in biological systems.163  
Along these lines, STAZN (stilbazulenyl nitrone) (Figure 28), a second generation 
of potent free radical scavenging azulenyl dinitrone was synthesized, starting from 
guiazulene.164 Preclinical studies of STAZN in a rodent stroke model showed very 
promising results.165-168 Lipid peroxidation analysis done on STAZN showed remarkable 
antioxidant activity compared to the widely studied spin traps such as PBN, NXY-059 and 
conventional antioxidants BHT, β-carotene and vitamin E.  In many investigations, 
STAZN has shown superior results compared to NXY-059 and some are similar to the 
compound Edaravone. Because of the high lipophilicity of STAZN, it readily crosses the 
BBB and it has a long circulating half-life with low toxicity.165-169 
 
Figure 28. Structure of stilbazulenyl nitrone (STAZN). 
3.4.3 Pseudoazulenes 
Pseudoazulenes are iso-π-electronic analogues of azulenes containing one or two 
heteroatoms (Figure 29). Pseudoazulenes possess some antifungal properties.170 These 
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molecules possess lower oxidation potentials than azulenes because of the presence of 
heteroatoms (more nucleophilic). Similarly, pseudoazulenyl nitrones are expected to have 
even lower oxidation potentials than azulenyl nitrones by virtue of the effect of 
conjugation. 
 
Figure 29. General structures of some Pseudoazulenes. 
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CHAPTER 4: SYNTHESIS OF PSEUDOAZULENYL NITRONES 
4.1 Design and synthetic efforts of pseudoazulenyl nitrones 
The objective of this research was to design and synthesize novel azulenyl nitrones 
with lower oxidation potentials to target ROS radical generation at the site of 
mitochondria.171 A predominant source of ROS free radical generation is mitochondria 
during the respiratory chain process. The matrix or inner membrane of mitochondria 
becomes nucleophilic as it pumps protons across the inner membrane. To target nitrones 
to mitochondria, a key strategy was to produce cationic molecules that are attracted to the 
mitochondrial matrix because of the large mitochondrial membrane potential.171-172 To 
implement this strategy, the objective was to synthesize the following molecules 104 and 
105 as potential therapeutic compounds.  
 
Figure 30. Structures of designed pseudoazulenyl nitrones. 
Many studies have been reported on mitochondrial dysfunction as well as possible 
strategies for mitochondrial drug delivery.171 The inner mitochondrial membrane (IMM) is 
a strong barrier to mediate passage of all kinds of molecules into the mitochondrial matrix. 
However, the major advantage of targeting mitochondria is that the IMM maintains a 
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strong negative potential that is requisite for the electron transport chain (and it is also rich 
in the phospholipid cardiolipin).173 Cationic compounds and a strong carbon backbone 
structure are attracted and accumulated within the negatively charged mitochondrial 
matrix.  
The electron donating group on the five membered ring of the pseudoazulene 
should increase electron density and lead to pseudoazulenes with extremely low oxidation 
potentials. The presence of the imidazole moiety may provide additional biological 
properties in that imidazole and its derivatives are known to target mitochondria.174 The 
imidazole functionality may also provide a platform to make cationic features needed to 
reach the inner region of the mitochondria. The dinitrone moieties are the main functional 
part of the target molecules, which play a crucial role in scavenging radicals similar to 
STAZN.  
 
Figure 31. Electronegative sites of pseudoazulenes. 
Reduction potentials play a crucial role in scavenging free radical moieties. It is 
very important to understand the redox chemistry of nitrones for their use as antioxidants. 
Previous studies showed that antioxidants with low oxidation potentials have greater free 
radical trapping ability in biological systems.164 Pseudoazulenes are rich in electrons and 
have lower oxidation potentials compared to azulenes.164, 175 Therefore, the plan was to 
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further lower the oxidation potential of pseudoazulenyl nitrones by rising the electron 
density in the five membered ring of the pseudoazulenyl system, which can be achieved by 
placing an electron donating group at the most electronegative position of the 
pseudoazulene (Figure 31).    
4.1.1 Extraction of valtrate and synthesis of baldrinal 
Valtrate was used as the starting compound for the synthesis of the pseudoazulenyl 
dinitrones. Valtrate was extracted from finely ground Centranthus ruber root by using 
ethanol as an extraction solvent (Scheme 24). The crude collected from the ethanol 
extraction was partially purified by chloroform extraction. To obtain pure valtrate 106, 
silica gel column chromatography is then required, using hexane/ethyl acetate as the mobile 
phase. The total yield of this extraction and purification method of valtrate depends 
extensively on the quality of the root used (on average it is 3% of the total mass of root 
used). The less expensive dried root Valeriana officinalis was also used to extract valtrate 
but the yield and effort were inferior. 
 
Scheme 23. Synthesis of baldrinal and compound 8. 
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The greenish colored oily liquid (valtrate) was treated with trifluoroacetic acid or 
trichloroacetic acid to get baldrinal, a yellow colored solid compound, which is the crucial 
precursor to synthesize various pseudoazulenyl dinitrone derivatives. Purification with 
silica gel column chromatography required the use of a hexane/ethyl acetate mixture in 
order to get pure baldrinal 107. This degradation reaction also led to another compound 
108, as a minor product. Compound 108 is similar to baldrinal in structure, containing a 
hydroxyl group at the position of the ester in baldrinal. Although the products are colored 
compounds, the purification process is very challenging as this reaction leads to a number 
of impurities with similar color (yellow), which significantly lowered the yields of both 
compounds: 20% for compound 107 and 11% for 108. 
4.1.2 Synthesis of pseudoazulenyl dicarbaldehyde with imidazole side chain 
The biogenic amine, histamine, engages in many physiological functions such as 
immune response and neurotransmission processes. Nitrones having histamine 
functionality are expected to target the mitochondrial matrix in order to scavenge generated 
free radicals, since the nitrogen on certain imidazole derivatives is anticipated to be 
protonated at physiological pH with the formation of a cationic quaternary salt. Therefore, 
the pseudoazulene compound containing an imidazole functionality, 2-(propyl imidazole)-
cyclopenta[c]pyridine-4,7-dicarbaldehyde, was synthesized from baldrinal 107 and 1-(3-
aminopropyl)imidazole 109 (Scheme 25) by following the method of Seitz et al.176 
Fortunately, both baldrinal and its derivative compound 108 provided the same product 
110. Therefore, it is not necessary to separate these two compounds 107 and 108 from their 
crude mixture in the above reaction in scheme 24.  
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Scheme 24. Synthesis of dialdehyde compound (110). 
 The reported yields of this method are very poor (around 20%) and the compound 
110 was obtained in 8.2% yield. It is also reported that the cyclopenta[c]pyridine analog of 
compound 108 is an intermediate during the process of converting baldrinal into the 
corresponding cyclopenta[c]pyridine.176 Autoxidation is involved in the oxidation of the 
hydroxyl side chain to yield the carbaldehyde.  
4.1.3 Synthesis of pseudoazulenyl mono and dinitrones 
Introducing an electron donating group at the more electronegative position of five-
membered ring of compound 110 was performed. The ethylthio substituted pseudoazulenyl 
dialdehyde 111 was synthesized in 24% yield by reacting dialdehyde compound 110 with 
ethyl sulfenyl chloride (Scheme 26), which is obtained from an in situ reaction between 
dietyldisulfide and sulfuryl chloride. The ethylthio substituted dialdehyde so obtained is 
then converted into pseudoazulenyl dinitrone 104, one of the target molecules, by treating 
with N-tert-butyl hydroxyl amine. In addition to the dinitrone compound, mononitrone 112 
was also obtained in a similar yield, 20% and 19%, respectively.  
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Scheme 25. Synthesis of dinitrone and mono nitrone. 
4.1.4 Attempts at making pseudoazulenyl dinitrone salts and Girard’s reagent 
derivatization (112)  
After successful synthesis of the ethylthio substituted pseudoazulenyl dinitrone, it 
was treated with allyl/benzylic chlorides (RCl) in a failed attempt to make a quaternary salt 
at the N-3 position. As an alternative, we turned our attention to derivatization of the 
aldehyde precursor 112 with Girard’s reagent to make cationic hydrazones. Girard’s 
reagent derivatives are effective in photoprotection of retinal pigment epithelial cells (RPE) 
by quenching singlet-oxygen species generated during photo oxidative stress.177  All 
attempts made on mono nitrone 112 failed to make Girard’s reagent derivatives at 35 °C 
and at rt (in both cases the mono nitrone decomposed).  
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Scheme 26: Reaction attempts to form quaternary salts and Girard’s reagent derivative. 
4.2 Conclusion regarding pseudoazulenyl nitrones synthesis  
 Mitochondria are the primary reason behind the life and death of many biological 
cells. They perform many physiological functions such as ATP production, apoptosis, 
amino acid-nitrogen metabolism, ROS generation and detoxification. However, these 
processes are not always under control. Excess generation of ROS in or at several sites of 
mitochondria can damage antioxidant defense systems in mitochondria, which leads to 
oxidative stress. Considerable research has been reported on developing therapeutic 
compounds with mitochondriotropic properties. Among those strategies, the large 
mitochondrial membrane potential is the major consideration, which can lead to the 
accumulation of cationic compounds within the mitochondrial matrix. This special 
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advantage has led to the discovery of bioavailable mitochondria targeted antioxidants such 
as Mitoquinone (MitoQ), Mitotocopherol (MitoVitE) and MitoTEMPOL.178  
 It is evident that nitrones are the most widely used compounds for spin trapping 
biogenic free radicals. It has been expected that the synthesis of particular cationic 
pseudoazulenyl nitrones may act as potent antioxidant compounds in order to target the 
mitochondrial matrix. In terms of synthesis of such pseudoazulenyl nitrones, compounds 
104 and 105 were chosen as synthetic targets. The major structural moiety in these target 
molecules is a pseudoazulene unit, which is obtained from a precursor that is extracted 
from Centranthus ruber, a natural root. The complications for synthetic chemists, working 
with natural compounds, such as poor yields and purification related problems are 
inevitable. However, the synthesis of one of the target compounds, the interesting dinitrone 
104, was successfully completed. Unfortunately, the attempts made to convert 104 into the 
corresponding cationic compound 105 failed. It will be necessary to carry these reactions 
in larger quantity from the beginning and make more dinitrone in order to try different 
strategies to synthesize various pseudoazulenyl nitrone cationic compounds. Also, a 
pseudoazulenyl mono nitrone compound with an electron donating group was synthesized 
by leaving a highly reactive aldehyde functionality intact for further use in synthetic study. 
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CHAPTER 5: EXPERIMENTAL SECTION 
3-((3-Methylisoxazol-5-yl)methyl)cyclohex-2-ene-1-one (44): 
To a solution of 3,5-dimethylisoxazole 42 (5.0 g, 51.5 mmol) in anhydrous THF 
(50 ml) was added 2.5 M n-BuLi in hexane (22.6 ml, 56.65 mmol, 1.1 eq) at  -78 °C via 
cannula over 20 min. The solution was stirred for 30 min at the same temperature, then 
added 3-ethoxycyclohex-2-ene-1-one 43 (7.2 g, 51.5 mmol) in one lot with vigorous 
stirring. The resulting reaction mixture was slowly brought back to the room temperature 
over 90 min period and stirred an additional 30 min. The resulting solution was then 
acidified with 2N HCl (35 ml), stirred 30 min more at same temperature and extracted with 
diethyl ether or chloroform (3 × 100 ml). The combined organics were washed with 
aqueous ammonium chloride and brine solutions, dried over MgSO4 and evaporated. The 
resulting residue was purified by silica gel column chromatography with 20% ethyl acetate 
in hexane as eluent to obtain enone product 44 (7.02 g , 71%) as a light orange colored 
semi solid. 
 
1H NMR: (400 MHz, CDCl3): δ 5.92 (s, 1H), 5.90 (t, J = 1.2 Hz, 1H), 3.62 (s, 2H), 2.38 
(t, J = 6.8 Hz, 2H), 2.33 (t, J = 5.8 Hz, 2H), 2.28 (s, 3H), 2.01 (m, 2H).  
13C NMR: (100 MHz, CDCl3): δ 199.17, 167.88, 160.04, 158.86, 127.88, 103.47, 37.12, 
35.04, 29.26, 22.52, 11.39.     
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3-((2,3-Dimethylisoxazol-5(2H)-ylidene)methyl)cyclohex-2-en-1-one (45): 
Trimethyloxonium tetrafluoroborate (5.48 g, 36.6 mmol) and the molten 3-((3-
methylisoxazol-5-yl)methyl)cyclohex-2-ene-1-one 44 (7.0 g, 36.6 mmol) were added into 
a two-neck dried flask. The resulting mixture stirred under argon until no solid remained. 
Then the reaction flask was evacuated, refilled with argon and kept at -78 °C. To this 
reaction mixture, a solution of 2.5 M n-BuLi in hexane (16.1 ml, 40.35 mmol, 1.1 eq) in 
60 ml of anhydrous THF was added dropwise via cannula over 30 min period. The resulting 
reaction mixture was slowly brought back to the rt over 90 min period and stirred an 
additional 30 min (excess pressure was released by keeping a argon gas filled balloon on 
top of reaction flask’s septum). To the resulting solution water (40 ml) was added and 
extracted with chloroform (3 × 100 ml). The combined organics were dried over anhydrous 
magnesium sulfate and the solvent was removed under vacuum in dark without heating. 
The resulting residue was purified by silica gel column chromatography with 10% 
methanol in chloroform as eluent to obtain isoxazole anhydrobase 45 (7.1 g, 74%) as a dark 
yellow colored solid. 
 
1H NMR: (400 MHz, CDCl3): δ 6.15 (s, 1H), 5.43 (s, 1H), 4.82 (s, 1H), 3.23 (s, 3H), 2.47 
(t, J = 6.0 Hz, 2H), 2.35 (t, J = 6.6 Hz, 2H), 2.07 (d, J = 0.4 Hz, 3H), 1.97 (m, 2H).  
13C NMR: (100 MHz, CDCl3): δ 198.3, 165.7, 158.7, 155.3, 116.6, 100.7, 88.1, 39.4, 36.6, 
30.0, 22.6, 10.9.   
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5-Methyl-2-(1-(methylamino)ethylidene)-3-(3-oxocyclohex-1-en-1-yl)-2,3,8,9-
tetrahydro-1H-cyclopenta[a]naphthalene-1,6(7H)-dione (46):  
 3-((2,3-dimethylisoxazol-5(2H)-ylidene)methyl)cyclohex-2-en-1-one 45 
(5.0 g, 24.3 mmol) was dissolved in anhydrous benzene (25 ml) and heated at 50 °C for 3 
hours. The resulting mixture was evaporated under vacuum and the residue was purified 
by silica gel column chromatography with 20% ethyl acetate in hexane as eluent to obtain 
dimer product 46 (0.5 g, 12%) as a red colored solid. 
 
1H NMR: (400 MHz, CDCl3): δ 10.90 (d, J = 4.8 Hz, 1H), 7.02 (s, 1H), 6.33 (s, 1H), 4.38 
(s, 1H), 3.64 (t, J = 6.0 Hz, 2H), 3.03 (d,  J = 5.2 Hz, 3H), 2.69-2.66 (m, 5H), 2.38 (m, 2H), 
2.11 (m, 2H) 2.02 (s, 3H), 1.98 (m, 2H), 1.78 (m, 2H).  
13C NMR: (100 MHz, CDCl3): δ 200.10, 199.73, 190.58, 167.05, 161.68, 151.18, 145.12, 
144.83, 135.50, 131.69, 128.18, 126.07, 105.62, 50.97, 41.06, 37.80, 29.64, 25.46, 24.37, 
24.17, 23.00, 22.59, 15.39.  
HRMS: (LC/MS, MeOH) m/z 364.19 (MH+).  
5,6-Dihydrobenzo[h]cinnolin-3(2H)-one (51):  
A reaction mixture of 1-tetralone 50 (1.0 g, 6.84 mmol), glyoxylic acid 
monohydrate (0.63 g, 6.84 mmol) and 1 ml of glacial acetic acid was stirred and heated at 
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110 °C for 1h. The resulting solution was cooled to 60 °C, dispersed in water (4 ml) and 
treated with ammonia solution to get pH9.  The basic solution was filtered to remove any 
unreacted 1-tetralone and treated with hydrazine hydrate (0.34 ml, 6.84 mmol). The 
resulting suspension was heated reflux at 120 °C for 1h. The formed yellow colored 
reaction mixture was cooled to rt and filtered, washed with water and recrystallized in 
aqueous ethanol. The resulting fairly pure solid compound was purified by silica gel 
column chromatography with hexane/acetone (4:1) as an eluent to obtain pale yellow 
colored solid product 51 (1.06 g, 79%).  
 
1H NMR: (400 MHz, DMSO): δ 13.00 (s, 1H), 7.91 (m, 1H), 7.36-7.29 (m, 3H), 6.79 (s, 
1H), 2.85 (m, 4H).  
13C NMR: (100 MHz, DMSO): δ 160.74, 144.16, 141.03, 137.64, 130.37, 129.22, 128.34, 
127.14, 125.37, 123.35, 27.58, 26.57.    
Diethyl 2-hydroxy-2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)malonate (53): 
 A reaction mixture of 1-tetralone 50 (0.1 g, 0.68 mmol) and diethyl ketomalonate 
(0.13 g, 0.75 mmol) in a dried flask was stirred and heated at 100 °C for 12 h. The resulting 
crude compound was purified by silica gel column chromatography with hexane/ethyl 
acetate (4:1) and obtained liquid product 53 (0.15 g, 70%).  
With n-BuLi: The same reaction was also carried out with n-BuLi. To a solution of 1-
tetralone 50 (1.0 g, 6.8 mmol) in anhydrous THF (40 ml) was added 2.5 M n-BuLi in 
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hexane (2.7 ml, 6.8 mmol) dropwise at -78 °C and stirred for 30 min. To this reaction 
mixture diethyl ketomalonate (1.2 g, 6.8 mmol) was added and stirred additional 30 min at 
same temperature. The resulting reaction mixture was slowly warmed to the rt, stirred 30 
min and acidified with acetic acid (5 ml). The resulting solution was extracted with 
chloroform (3 × 100 ml). The combined organics were washed with brine, dried over 
anhydrous magnesium sulfate and evaporated. The formed residue purified by silica gel 
column chromatography with hexane/ethyl acetate (9:1) as an eluent to obtain pure liquid 
product 53 (0.85 g, 40%).  
 
1H NMR: (400 MHz, CDCl3): δ 8.00 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.27 (m, 
2H), 4.33 (m, 4H), 4.05 (d, J = 0.8 Hz, 1H), 3.79-3.71 (m, 1H), 3.23-2.99 (m, 2H), 2.31-
2.13 (m, 2H), 1.31 (m, 6H).  
13C NMR: (100 MHz, CDCl3): δ 195.72, 170.54, 169.47, 143.94, 133.79, 132.13, 128.70, 
127.62, 126.74, 79.82, 62.98, 62.75, 53.40, 29.11, 24.53, 14.09, 13.97.     
2-(3,4-Dihydronaphthalen-1(2H)-ylidene)hydrazine-1-carboximidamide (56): 
 A reaction mixture of aminoguanidine hydrochloride (0.75 g, 6.8 mmol), 1-
tetralone 50 (1.0 g, 6.8 mmol) and 2 ml of methanol was stirred for five minutes, added 
concentrated sulfuric acid (0.5 ml) and warmed to 40 °C. The resulting reaction mixture 
was stirred for 1h, added a solution of KOH in methanol (1.0 gm of KOH in 5 ml of 
methanol) and stirred additional 15 min. The reaction suspension was filtered and the 
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filtrate was diluted with water, adjusted pH 13 using aqueous NaOH. The resulting basic 
solution was then extracted rapidly with ethyl acetate and the organics dried over calcium 
chloride and evaporated. The residue obtained from organic layers was purified by silica 
gel column chromatography with 10% methanol in chloroform as an eluent to obtain pure 
solid product of 56 (0.8 g, 62%).  
 
2-Cyano-N'-(3,4-dihydronaphthalen-1(2H)-ylidene)acetohydrazide (58): 
 To a solution of 1-tetralone 50 (0.5 g, 3.4 mmol) in 5 ml of ethanol was added 
cyanoacetohydrazide (0.34, 3.4 mmol) and heated at 80 °C for 5h in presence of catalytic 
amount of piperidine as a catalyst. The resulting reaction mixture was brought back to rt 
and continued stirring overnight. The reaction residue, after evaporation of solvent 
remained, was purified by silica gel column chromatography with chloroform/methanol 
(9:1) as eluent to obtain pure product 58 (0.6 g, 78%).  
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1H NMR: (400 MHz, CDCl3): δ 9.61 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.31 (m, 1H), 7.25 
(m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 3.96 (s, 2H), 2.80 (t, J = 6.4 Hz, 2H), 2.62 (t, J = 6.8 Hz, 
2H), 2.00 (m, 2H).  
3,4-Dihydronaphthalen-1(2H)-one oxime (64):  
 To a solution of 1-tetralone 50 (0.5 g, 3.4 mmol) in 1:1 ratio of pyridine: ethanol 
mixture (10 ml) was added hydroxylamine hydrochloride (0.47 g, 6.8 mmol) and stirred 
over 20-30 min at rt. The resulting reaction mixture was acidified by pouring it into 2N 
hydrochloric acid (15 ml) and extracted with dichloromethane. The combined organics 
were dried over anhydrous magnesium sulfate and evaporated. The formed solid residue 
(oxime product 64) (0.5 g, 90%) was pure enough to use in further reactions (silica gel 
column chromatography can be used with hexane/acetone (4:1) as eluent, to remove any 
impurities showed on TLC). 
 
1H NMR: (400 MHz, CDCl3): δ 8.08 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.27 (m, 1H), 7.20 
(m, 1H), 7.16 (m, 1H), 2.82 (t, J = 6.8 Hz, 2H), 2.77 (t, J = 6.0 Hz, 2H), 1.87 (m, 2H).  
3,4-Dihydronaphthalen-1(2H)-one O-tosyl oxime (65): 
 To a solution of P-TsCl (0.53 g, 2.78 mmol) in anhydrous pyridine (2 ml) was added 
an ice cold solution of 3,4-dihydronaphthalen-1(2H)-one oxime 64 (0.45 g, 2.78 mmol) in 
pyridine (2 ml) dropwise and stirred for 16 hours at rt. The resulting reaction mixture was 
quenched with water and extracted with chloroform. The combined organics were washed 
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with 2N HCl, 0.5 M NaHCO3 and brine solution. The resulting organic solution was 
evaporated and the residue was purified by silica gel column chromatography with 
hexane:acetone (4:1) as eluent to obtain pure tosylated oxime 65 (0.48 g, 55%).  
 
1H NMR: (400 MHz, CDCl3): δ 7.94 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.35 (d, 
J = 8.0 Hz, 2H), 7.30 (m, 1H), 7.16 (m, 2H), 2.83 (t, J = 6.8 Hz, 2H), 2.73 (t, J = 6.4 Hz, 
2H), 1.82 (m, 2H).  
Diethyl ((4-methyl-1,2,5-oxadiazol-3-yl)methyl)phosphonate (72): 
 To a solution of 3,4-dimethylfurazan 69 (1.0 g, 10.2 mmol) in anhydrous THF (20 
ml) was added 2.5 M n-BuLi in hexane (4.45 ml, 11.22 mmol, 1.1 eq) dropwise at -78 °C 
and stirred for 1h. The reaction mixture turned from clear solution to greenish yellow 
colored. Diethylchlorophosphate (2.11 g, 1.2 eq) was added, stirred for 30 min. The 
reaction mixture was brought back to rt over 90 min, stirred for additional 30 min and 
added water (10ml). The resulting solution was extracted with chloroform, washed with 
ammonium chloride and brine solution. The combined organics evaporated and the residue 
was purified by silica gel column chromatography with hexane/ethylacetate (4:1) as an 
eluent to obtain pure phosphoester product 72 (0.85 g, 36%). KMnO4 staining system was 
used for TLC.  
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1H NMR: (400 MHz, CDCl3): δ 4.12 (m, 4H), 3.32 (s, 1H), 3.27 (s, 1H), 2.45 (s, 3H), 1.31 
(t, J = 11.6 Hz, 6H). 
 13C NMR: (100 MHz, CDCl3): δ 151.22, 151.20, 147.52, 147.46, 62.92, 62.86, 22.70, 
21.28, 16.31, 16.25, 8.22.  
N-(4H-1,2,4-triazol-4-yl)-3,4-dihydronaphthalen-1(2H)-imine (74): 
 A mixture of 1-tetralone 50 (1.0 g, 6.8 mmol) and 4-amino-4H-1,2,4-tirazole 73 
(0.57 g, 6.8 mmol) was heated at 100 °C for 2h in presence of molecular sieves (4 A°). The 
resulting reaction residue was purified by silica gel column chromatography with 
chloroform/methanol (9:1) to obtain pure hydrazone 74 (1.2 g, 83%) as a red colored solid 
product.  
 
1H NMR: (400 MHz, CDCl3): δ 8.27 (m, 3H), 7.47 (m, 1H), 7.33 (t, J = 7.2 Hz, 1H), 7.27 
(d, J = 8.0 Hz, 1H), 2.94 (t, J = 6.0, 2H), 2.68 (t, J = 6.4, 2H), 1.98 (m, J = 6.4, 2H).  
 13C NMR: (100 MHz, CDCl3): δ 172.69, 142.05, 139.77, 132.57, 129.87, 129.17, 126.92, 
126.36, 29.38, 28.41, 22.35.  
5,8-Dimethyl-N-(4H-1,2,4-triazol-4-yl)-3,4-dihydronaphthalen-1(2H)-imine (78): 
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A mixture of 5,8-dimethyl-1-tetralone 77 (20 mg, 0.11 mmol) and 4-amino-4H-
1,2,4-tirazole 73 (20 mg, 0.22 mmol) was heated at 100 °C for 3h in presence scandium 
triflate (15 mol%). The resulting reaction residue was purified by silica gel column 
chromatography with chloroform/methanol (9:1) to obtain corresponding pure hydrazone 
78 (11 mg, 40%) as a solid product.  
 
1H NMR: (400 MHz, CDCl3): δ 8.22 (s, 2H), 7.21 (d, J = 7.6 Hz, 1H), 7.7.11 (d, J = 8.0 
Hz, 1H), 2.77 (t, J = 6.4 Hz, 2H), 2.65 (t, J = 6.4 Hz, 2H), 2.60 (s, 3H), 2.29 (s, 3H), 1.93 
(m, J = 6.4 Hz, 2H).  
 13C NMR: (100 MHz, CDCl3): δ 176.36, 141.13, 139.61, 136.76, 133.60, 132.76, 130.22, 
129.73, 28.82, 26.71, 23.80, 21.75, 19.61.  
3-(3-((4H-1,2,4-triazol-4-yl)imino)cyclohex-1-en-1-yl)-5-methyl-2-(1-
(methylamino)ethylidene)-2,3,8,9-tetrahydro-1H-cyclopenta[a]naphthalene-1,6(7H)-
dione (75): 
A mixture of dimer compound 46 (0.1 g, 0.27 mmol) and 4-amino-4H-1,2,4-
tirazole 73 (45 mg, 0.54 mmol) was heated at 100 °C for 1h. The resulting reaction residue 
was purified by silica gel column chromatography with chloroform/methanol (9:1) to 
obtain pure mono-hydrazone 75 (83 mg, 71%) as a red colored solid product (both isomers 
E&Z in 3:1 ratio).  
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1H NMR: (400 MHz, CDCl3): δ 10.90 (m, 1H), 8.27 and 8.22 (s, 2H), 7.06 and 6.86 (s, 
1H), 6.68 and 6.35 (s, 1H), 4.47 and 4.27 (s, 1H), 3.64 (m, 2H), 3.04 (d, J = 5.6, 3H), 2.69 
(m, 5H), 2.44 (m, 2H), 2.07 (s, 3H), 2.12 (m, 2H), 2.01 (m, 2H), 1.78 (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 200.07, 199.99, 190.52, 190.39, 173.18, 173.08, 166.69, 
161.70, 161.57, 161.30, 151.15, 150.57, 145.15, 145.06, 144.95, 144.87, 139.90, 139.70, 
135.46, 131.82, 131.68, 125.93, 125.70, 124.06, 123.82, 115.44, 105.44, 105.41, 51.34, 
50.97, 41.00, 31.49, 29.61, 27.05, 26.34, 25.42, 24.90, 24.16, 24.01, 22.54, 22.50, 22.19, 
21.97, 15.43, 15.32.  
HRMS: (LC/MS, MeOH) m/z 430.22 (MH+).  
6-((4H-1,2,4-triazol-4-yl)imino)-3-(3-((4H-1,2,4-triazol-4-yl)imino)cyclohex-1-en-1-
yl)-5-methyl-2-(1-(methylamino)ethylidene)-2,3,6,7,8,9-hexahydro-1H-
cyclopenta[a]naphthalen-1-one (76): 
A mixture of dimer compound 46 (1.0 g, 2.75 mmol) and 4-amino-4H-1,2,4-
tirazole 73 (0.92 g, 10.90 mmol) was heated at 100 °C for 3h in presence of scandium 
triflate (0.2 g, 15 mole percent). The resulting reaction residue was purified by silica gel 
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column chromatography with chloroform/methanol (9:1) to obtain pure bis-hydrazone 76 
(0.4 g, 30%) along with the monohydrazone compound 75 (0.41 g, 35%).  
 
1H NMR: (400 MHz, CDCl3): δ 10.93 (m, 1H), 8.24 (t, 4H), 7.17 and 6.97 (s, 1H), 6.70 
and 6.36 (s, 1H) 4.50 and 4.29 (s, 1H), 3.63 (m, 1H), 3.50 (m, 1H), 3.04 (m, 3H), 2.71 (m, 
2H), 2.80 (s, 3H) 2.45 (m, 2H), 2.09 (s, 3H), 1.90 (m, 4H), 1.63 (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 190.20, 190.07, 175.24, 175.11, 173.10, 166.63, 161.97, 
161.61, 150.15, 149.57, 142.88, 142.81, 142.53, 142.42, 139.97, 139.76, 139.61, 135.25, 
135.19, 130.29, 130.10, 126.31, 126.04, 123.95, 115.53, 105.52, 51.30, 50.93, 31.53, 81  
29.75, 29.71, 29.28, 27.12, 24.96, 24.84, 24.36, 24.31, 24.04, 22.25, 22.05, 21.46, 15.57, 
15.46, 14.15. 
HRMS: (LC/MS, MeOH) m/z 496.26 (MH+).  
6-((4H-1,2,4-triazol-4-yl)imino)-5-methyl-2-(1-(methylamino)ethylidene)-3-(3-
oxocyclohex-1-en-1-yl)-2,3,6,7,8,9-hexahydro-1H-cyclopenta[a]naphthalen-1-one 
(48): 
 To a solution of bis-hydrazone compound 76 (0.1 g, 0.2 mmol) in 3 ml of THF was 
added a solution of cupric chloride (27 mg, 0.2 mmol) in water (4 ml) dropwise at rt and 
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stirred for 10h (the reaction progress was carefully followed by TLC and quenched with 
ammonium hydroxide when TLC started forming dimer compound 46). The resulting 
reaction mixture was extracted with chloroform, washed with brine solution and dried over 
anhydrous magnesium sulfate. The residue formed on evaporation was purified by silica 
gel column chromatography with chloroform/methanol (9:1) to obtain pure product 48 (28 
mg, 33%) as brown colored solid.  
 
1H NMR: (400 MHz, CDCl3): δ 10.90 (d, J = 5.2, 1H), 8.23 (s, 2H), 7.12 (s, 1H), 6.32 (s, 
1H), 4.39 (s, 1H), 3.64-3.55 (m, 1H), 3.51-3.43 (m, 1H), 3.03 (d, J = 5.2, 3H), 2.70 (t, J = 
6.8, 2H), 2.65 (s, 3H) 2.36 (m, 2H), 2.02 (s, 3H), 1.95 (m, 2H), 1.82 (m, 2H), 1.61 (m, 2H).   
13C NMR: (100 MHz, CDCl3): δ 199.63, 190.09, 175.22, 166.86, 161.98, 150.09, 142.72, 
142.26, 139.53, 135.19, 129.98, 128.13, 126.32, 105.61, 50.81, 37.72, 29.61, 29.19, 24.63, 
24.35, 24.27, 22.95, 21.39, 15.36.   
HRMS: (LC/MS, MeOH) m/z 430.22 (MH+).  
Extraction of 4-(acetoxymethyl)-6,7a-dihydro-1H-spiro[cyclopenta[c]pyran-7,2'-
oxirane]-1,6-diyl bis(3-methylbutanoate) (Valtrate, 106): 
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A finely grounded Centranthus ruber root (100 g) was stirred in ethanol (800 ml) 
for overnight at rt. The thick paste of crude compound, obtained from vacuum filtration 
and evaporation of ethanol, was dissolved in chloroform and filtered. The residue collected 
from chloroform was purified by silica gel column chromatography with hexane/ethyl 
acetate (4:1) to obtain pure valtrate (4.0 g) as a green colored oil. 
 
1H NMR: (400 MHz, CDCl3):  δ 6.69 (s, 1H), 5.98 (d, J = 10.0 Hz, 1H), 5.86 (t, J = 2.8 
Hz, 1H), 5.37 (d, J = 2.8 Hz, 1H), 4.70 (dd, J = 28.4 Hz and 12.4 Hz, 2H), 3.43 (dd, J = 10 
Hz and 2.45 Hz, 1H), 2.95 (dd, J = 47.3 Hz and 4.7 Hz, 2H), 2.23 (m, 2H), 2.21 (m, 2H), 
2.08 (m, 2H), 2.04 (s, 3H), 0.97 (d, J = 6.5 Hz, 6H), 0.93 (d, J = 6.5 Hz, 6H). 
 13C NMR: (100 MHz, CDCl3): δ 172.45, 170.8, 170.25, 148.45, 140.9, 117.8, 108.4, 92.6, 
83.0, 64.15, 60.8, 47.8, 43.35, 43.0, 25.8, 25.5, 22.3, 22.1, and 20.90.  
LRMS: (LC/MS, MeOH) m/z 423.1 (MH+). 
(7-Formylcyclopenta[c]pyran-4-yl)methyl acetate (Baldrinal, 107):  
To a solution of valtrate (7.3 g, 17.3 mmol) in chloroform (20 ml) was added a 
solution of trifluroacetic acid (15.7 g, 8.0 eq) in 35 ml of chloroform and stirred at rt. The 
dark green color appeared in 10 min and the reaction mixture was diluted with chloroform 
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(100 ml) by following the disappearance of valtrate spot on TLC. The pH of the resulting 
solution was adjusted to 7 by using a mixture of saturated aqueous NaCl and saturated 
aqueous NaHCO3 solutions. The yellow colored organic layers were collected by 
successive extractions with chloroform (3 × 100 ml), dried over anhydrous magnesium 
sulfate and evaporated. The collected residue was purified by silica gel column 
chromatography with hexane/ethyl acetate (7:3) as an eluent to obtain pure baldrinal 
compound 107 (0.75 g, 20%) as a yellow colored solid. 
 
1H NMR: (400 MHz, CDCl3): δ 9.94 (s, 1H), 9.19 (s, 1H), 7.89 (s, 1H), 7.87 (d, J = 3.2 
Hz, 1H), 6.61 (dd, J = 3.2 Hz and 0.4 Hz, 1H), 5.26 (d, J = 0.8 Hz, 2H), 2.13 (s, 3H).  
13C NMR: (100 MHz, CDCl3): δ 185.0, 170.72, 150.78, 146.32, 133.90, 125.00, 123.12, 
119.45, 109.63, 60.57, 20.88. 
LRMS: (LC/MS, MeOH) m/z 219.02 (MH+). 
2-(Propyl imidazole)-cyclopenta[c]pyridine-4,7-dicarbaldehyde (110): 
To a solution of baldrinal 107 (2.0g, 9.15 mmol) in 5 ml of chloroform was added 
1-(3-aminopropyl)-imidazole 109 (2.3 g, 18.3 mmol) with vigorous stirring at rt. The dark 
yellow color of the baldrinal changed to dark red and the reaction was stopped by following 
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the disappearance of baldrinal spot on TLC. The solvent was evaporated and the collected 
crude compound was purified by silica gel column chromatography with 15% methanol in 
chloroform to obtain a pure dialdehyde 110 (210 mg, 8.2%) as a red colored solid.  
 
1H NMR: (400 MHz, CDCl3): δ 10.23 (s, 1H), 9.93 (s, 1H), 9.02 (s, 1H), 8.00 (d, J = 3.6 
Hz, 1H), 7.73 (d, J = 1.6 Hz, 1H), 7.59 (s, 1H), 7.25 (s, 1H), 7.16 (s, 1H), 6.96 (s, 1H), 4.28 
(t, J = 6.8 Hz, 2H), 4.09 (t, J = 6.8, 2H), 2.53 (m, J = 6.8 Hz, 2H).  
13C NMR: (100 MHz, CDCl3): δ 189.12, 185.14, 145.92, 137.01, 133.62, 132.40, 130.52, 
127.68, 122.00, 121.19, 118.51, 108.21, 55.92, 43.51, 32.52.  
LRMS: (LC/MS, MeOH) m/z 282.12 (MH+). 
Synthesis of sulfenyl chloride: 
To a solution of sulfuryl chloride (110.4 mg, 0.82 mmol) in anhydrous methylene 
chloride (5 ml) was added another solution of 1,2-diethyldisulfide (100 mg, 0.82 mmol) in 
anhydrous methylene chloride (3 ml) dropwise over a period of 10 min at 0 °C. The 
resulting solution, containing freshly prepared sulfenyl chloride, kept at -70 °C for further 
synthetic use.  
 
5-Ethylthio-2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dicarbaldehyde (111):  
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To a solution of dialdehyde compound 110 (210 mg, 0.74 mmol) in a mixture of 
1:1 ratio of anhydrous hexane and anhydrous methylene chloride (20 ml) was added a 
freshly prepared and cooled (-70 °C) ethyl sulfenyl chloride (7.5 ml, 0.75 mmol) dropwise 
over a period of 30 min with vigorous stirring and frequent evacuation. The resulting 
reaction mixture was continued stirring for additional 30 min and brought back to rt 
gradually over a period of 100 min. At this point, the red of the solution turned green. The 
resulting solution was partitioned between chloroform and saturated aqueous sodium 
bicarbonate. The combined organics were washed with brine solution, dried over 
anhydrous magnesium sulfate and evaporated. The organic residue was purified by silica 
gel column chromatography with 15% methanol in chloroform to obtain pure sulfenylated 
dialdehyde compound 111 (62 mg, 24%) as a red colored solid. 
 
1H NMR: (400 MHz, CDCl3): δ 11.65 (s, 1H), 9.89 (s, 1H), 9.04 (d, J = 1.6 Hz, 1H), 7.99 
(d, J = 1.6 Hz, 1H), 7.94 (s, 1H), 7.53 (s, 1H), 7.15 (s, 1H), 6.96 (s, 1H), 4.26 (t, J = 6.8 
Hz, 2H), 4.08 (t, J = 6.8 Hz, 2H), 2.78 (m, J = 7.2 Hz, 2H), 2.50 (m, J = 6.8 Hz, 2H), 1.23 
(t, J = 7.2 Hz, 3H).  
13C NMR: (100 MHz, CDCl3): δ 190.76, 184.62, 150.05, 136.99, 135.39, 133.66, 130.53, 
128.73, 127.64, 123.73, 120.97, 118.50, 109.18, 56.21, 43.50, 32.62, 31.67, 14.96.   
 86 
 
LRMS: (LC/MS, MeOH) m/z 342.13 (MH+).  
5-Ethylthio-2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone (104) and 1-(2-
(3-(1H-imidazol-1-yl)propyl)-5-(ethylthio)-7-formyl-2H-cyclopenta[c]pyridin-4-yl)-
N-(tert-butyl)methanimine oxide (112):  
To a solution of 5-ethylthio-2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde 111 (62 mg, 0.18 mmol) in pyridine (3 ml) was added N-t-
butylhydroxylamine hydrochloride (115 mg, 0.9 mmol) and anhydrous magnesium sulfate 
(110 mg, 0.9 mmol) in a dried flask. The reaction mixture was stirred for 72h at 35 °C 
under argon. The resulting reaction mixture was partitioned between a saturated solution 
of aqueous sodium carbonate and chloroform. The combined organics were washed with 
brine solution, dried over anhydrous magnesium sulfate and evaporated. The crude residue 
was purified by silica gel column chromatography with CHCl3/MeOH/N(CH3)3 mixture 
(83:15:2) to obtain pure compounds of mono nitrone 112 (14 mg, 19%) and dinitrone 104 
(15 mg, 20%) as a red colored solids. The pure compounds were washed with saturated 
sodium thiosulfate, before storage, to avoid oxidation in presence of air.   
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Mono nitrone data: 
1H NMR: (400 MHz, CDCl3): δ 10.08 (d, J = 1.6 Hz, 1H), 9.96 (s, 1H), 9.84 (s, 1H), 9.04 
(d, J = 1.6 Hz, 1H), 7.82 (s, 1H), 7.56 (s, 1H), 7.12 (s, 1H), 6.98 (s, 1H), 4.25 (t, J = 6.8 
Hz, 2H), 4.06 (t, J = 6.8 Hz, 2H), 2.71 (m, J = 7.2 Hz, 2H), 2.51 (m, J = 6.8 Hz, 2H), 1.68 
(s, 12H), 1.18 (t, J = 7.2 Hz, 3H).  
Dinitrone Data: 
1H NMR: (400 MHz, CDCl3): δ 9.99 (s, 1H), 9.86 (s, 1H), 9.84 (s, 1H), 7.77 (s, 1H), 7.67 
(s, 1H), 7.62 (s, 1H), 7.10 (s, 1H), 7.01 (s, 1H), 4.20 (t, J = 7.2 Hz, 2H), 4.04 (t, J = 7.2 Hz, 
2H), 2.70 (m, J = 7.2 Hz, 2H), 2.48 (m, J = 7.2 Hz, 2H), 1.68 (s, 12H), 1.63 (s, 12H) 1.16 
(t, J = 7.2 Hz, 3H).  
13C NMR: (100 MHz, CDCl3): δ 144.23, 137.24, 136.95, 131.21, 129.94, 126.03, 125.92, 
124.85, 118.77, 118.48, 111.44, 106.56, 71.69, 67.84, 55.94, 43.66, 32.18, 29.34, 28.54, 
28.40, 14.74. 
HRMS: (LC/MS, MeOH) m/z 484.27 (MH+).  
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